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ABSTRACT
CLINICAL PREDICTORS OF DRUG RESISTANCE AND MORTALITY AMONG TUBERCULOSIS
PATIENTS IN A RURAL SOUTH AFRICAN HOSPITAL: A CASE-CONTROL STUDY
Jason R. Andrews, Neel R. Gandhi, Anthony P. Moll, Gerald H. Friedland. Yale AIDS Program,
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT.
The recent discovery of a high prevalence of multidrug-resistant (MDR-TB) and
extensively drug-resistant tuberculosis (XDR-TB) in rural South Africa, where HIV is rampant,
has provoked alarms about the future of tuberculosis control in the region. Little is known about
the clinical manifestations of MDR-TB in general, and XDR-TB in particular, in the high HIV
prevalence settings of Sub-Saharan Africa.
We performed a retrospective, case-control study of patients diagnosed with tuberculosis
at a rural hospital in KwaZulu Natal, South Africa, where large numbers of MDR-TB and XDRTB cases have been identified. All MDR-TB and XDR-TB patients who began treatment for TB
between June 1, 2005 and August 31, 2006 and whose charts were available were included in the
study. A comparison group of patients without resistance to both isoniazid and rifampicin (nonMDR-TB), matched 1:1 with the size of the MDR-TB and XDR-TB groups, was created.
Clinical and laboratory data were obtained through review of hospital records, clinic registers,
and the laboratory system. We compared clinical characteristics to identify risk factors for MDRTB, XDR-TB, and mortality. Bivariate and multivariate analyses were performed.
A total of 170 patients were enrolled in the study: 52 MDR-TB, 61 XDR-TB and 57 nonMDR-TB. Greater than 75% of patients from all groups were tested for HIV; HIV prevalence
among those tested was 94% in the non-MDR group, 93% in the MDR group, and 100% in the
XDR-TB group (P=1.000 for MDR versus non-MDR; p=0.089 for XDR versus non-MDR).
Forty percent of MDR-TB patients and 57% of XDR-TB patients had no previous history of TB
treatment, strongly suggesting transmitted drug resistance.
Significant associations and risk factors for MDR-TB and XDR-TB in bivariate analysis
included positive sputum smear (P=0.015, P=0.005), TB treatment in the past year (P<0.0001,
P<0.001), and hospitalization in the past two years (P=0.007, P=0.004). In multivariate logistic
regression, positive sputum smear remained a significant risk factor for XDR-TB (adjusted odds
ratio (AOR) 2.79, 1.20-6.47), and TB treatment in the past year remained a risk factor for both
MDR-TB and XDR-TB (AOR 8.33, 95% CI 1.64-42.33; AOR 7.19, 95% CI 1.35-38.17).
Mortality for the non-MDR, MDR and XDR groups was 36.8%, 73.1% and 85.3%,
respectively (P= 0.0001 for MDR versus non MDR; P<0.0001 for XDR versus non-MDR;
P=0.109 for XDR versus MDR); median survival from TB diagnosis was 199 days, 103 days, and
92 days, respectively (P<0.001). In Cox Proportional Hazards model, positive sputum smear
(P=0.003), MDR-TB (P=0.028), XDR-TB (P=0.002), and CD4 cell count less than 200
cells/mm3 (P=0.037) were significant risk factors for mortality.
Forty of the 170 patients had sputum isolates with differing resistance patterns, and 18
moved from a lower to a higher resistance category; this increasing drug resistance appeared to be
more likely the result of super-infection than amplification.
A significant proportion of MDR-TB and all XDR-TB appear to be due to primary
resistance, with nosocomial transmission playing a critical role. MDR-TB and XDR-TB carry
extraordinarily high mortality rates in this setting; previous hospitalization, previous TB
treatment, positive sputum smear and low CD4 count may be used to target drug susceptibility
testing for patients at high risk of drug resistant TB and mortality.
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INTRODUCTION
Tuberculosis and South Africa
Despite the availability of effective diagnostic, preventive, and curative
technologies, tuberculosis (TB) remains the number one cause of adult deaths by a
curable infectious disease worldwide (1). In 2004, the last year for which global TB
estimates are available, there were an estimated 9 million new cases and 14.6 million
prevalent cases of tuberculosis, resulting in 3-4 million deaths (2). Control of the disease
has been highly uneven across various parts of the world. While incidence has declined
dramatically since the early 19th century in the industrialized world, worldwide incidence
has been slowly increasing in recent years, largely as a result of dramatic rises in the
former Soviet Union and Africa (2, 3).
The developing world now bears 95% of all cases of TB, of which 70% occur on
two continents: Asia and Africa.(2). Countries of Sub-Saharan Africa have witnessed the
worst trends in recent years. Poor health infrastructure and a scarcity of human and
financial resources have combined with soaring HIV rates to effect a dramatic rise in TB
incidence in this region (4-6). Eight of the top ten countries by TB incidence are in SubSaharan Africa, and the average incidence among these countries is 4 times the global
rate and 140 times that of the United States (2). Mortality from tuberculosis is likewise
disproportionately high in the developing world, in general, and in Sub-Saharan Africa,
in particular. 98% of all deaths from TB occur in developing countries. Africa has the
highest mortality rates and lowest treatment success rates of any region in the world (2).
Within Africa, South Africa has the second highest TB incidence and the highest
number of reported TB cases. Approximately 339,000 cases of tuberculosis occur every
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year, resulting in an estimated 64,000 deaths (2). Sixty percent of all incident cases occur
in people infected with HIV. As TB incidence and prevalence continue to rise, DOTS
case detection rate has actually been falling in recent years, making evident the struggle
that the public health infrastructure is facing in meeting the demands of the growing
disease burden. The DOTS treatment success rate was 67% nationwide in 2003, well
below the WHO’s standard of 85% for DOTS programs, and in some areas is
substantially lower.

Review of Tuberculosis Drug Resistance
Since the introduction of the first effective anti-TB drug, streptomycin, in the late
1940’s, resistance of Mycobacterium tuberculosis to chemotherapeutic agents has been
understood as a major problem in the management of TB disease. Clinical relapse after
three to six months of improvement was observed in the earliest studies of streptomycin
(7, 8). Randomized controlled trials carried out by British researchers upon the
introduction of PAS in 1948 found that patients receiving combined therapy (PAS and
SM) had lower rates of relapse than those receiving either drug alone (9, 10). M.
tuberculosis has been able to acquire resistance to every effective chemotherapeutic agent
used against it.
Tuberculosis drug resistance can be either primary (transmission of resistant
organisms) or secondary (resistance acquired in the host related to inadequate treatment).
There are four broad categories of mechanisms of acquired resistance to drugs by M.
tuberculosis: 1) the creation of a lipid-rich cell wall that can reduce the permeability of
drugs (and arrest phagasome maturation); 2) the production of enzymes that degrade or
modify compounds, rendering them useless; 3) the efflux of drugs through protein
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pumps, described for isoniazid and ethambutol; and 4) spontaneous chromosomal
mutations that affect key drug targets (11-14). Among these, the fourth mechanism is
considered to be the most important. Mobile or horizontal transmission of resistance,
such as plasmid mediated resistance, does not occur in M. tuberculosis. Random genetic
mutations occur with low but predictable frequencies in the range of one mutation per 106
to 109 organisms. The frequency of mutations conferring resistance to particular agents
varies from the range of 10-3 for many second line drugs (thiacetazone, ethionamide,
capreomycin, cycloserine, and viomycin) to an intermediate level (around 10-6) for some
first and second line drugs (isoniazid, streptomycin, ethambutol, kanamycin, and pamino salicylic acid) to the lowest levels for rifampicin, on the order of 10-8 to 10-10.
When large populations of M. tuberculosis are formed in a host and selective pressure is
placed by a chemotherapeutic agent, the small population of M. tuberculosis that has
evolved resistance to the agent will continue to multiply while the susceptible M.
tuberculosis is suppressed. This enables the drug resistant organism to become the
dominant organism in the host.
In order to prevent this scenario from occurring, the central strategies in therapy
are to: 1) administer several chemotherapeutic agents, such that if there are organisms
resistant to one or two agents, they will be killed by the other agents; 2) provide therapy
for an adequate duration in order to ensure eradication of populations of M. tuberculosis,
which evades both host immune response and drug actions by a number of intricate
cellular mechanisms (14). Because the probability of two simultaneous mutations—the
product of the individual probabilities of mutations—is small (10-11 to 10-14) compared
with typical bacillary loads (up to 109 in a pulmonary cavity), the sustained presence of
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two or more effective drugs should eradicate the entire population of bacilli (this
traditional model, while useful, is an oversimplification due to the formation of
microenvironments with differing drug concentrations and activities) (14). The time
period of acquired resistance under monotherapy varies between agents and has been well
characterized for many of the initial anti-TB agents; in a 1952 study of isoniazid
monotherapy, 11%, 52% and 71% of patients developed resistant strains after one, two
and three months, respectively (15).
Not surprisingly, the most common ways in which M. tuberculosis drug resistance
evolves or amplifies in the host involve the violation of these principles. The causes of
these violations range widely, from the actions of the individuals, by nonadherence, to
those of the health provider, by improper regimen selection or suboptimal dosing, to the
failure of TB control programs to provide a consistent supply of necessary agents (11).
Understanding of these causes has evolved considerably over the past two decades,
trending towards increasing recognition of the impact of the social, economic and
political environments in which therapy takes place upon the likelihood that patients will
be exposed to the proper treatment for an adequate duration (16, 17).
Numerous host factors have been implicated in the facilitation of acquired drug
resistance, including the development of local tissue microenvironments recalcitrant to
antibiotic penetration or activity and the failure of the immune system to act in synergy
with antibiotic activity (14). Compromise of the host immune response, such as that
caused by infection with HIV, may be a significant risk factor for the evolution of drug
resistance. This is discussed in more detail below.
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More recently, the use of chemotherapeutic agents with efficacy against
tuberculosis for treatment and prophylaxis of other diseases has been implicated in the
development of resistance to these drugs by M. tuberculosis. This includes empiric use
of quinolones for community acquired pneumonia, when in fact the patient is manifesting
tuberculosis, or aminoglycosides for a number of diseases (18-20); both are important
second line tuberculosis classes that are widely used in routine clinical practice for the
treatment of other diseases.. The duration of exposure required for resistance to evolve
has not been well characterized yet; nevertheless, this has led some high TB-prevalence
countries to regulate empiric use of these classes of drugs. The use of rifamycins in the
prophylaxis of mycobacterium avium-intracellulare disease has been associated with the
development of rifampicin-resistant TB in HIV patients (21, 22).
Finally, there exists considerable cross-resistance and class-resistance to
antituberculosis agents. All rifamycins have high levels of cross resistance (23, 24).
Fluoroquinolones have considerable cross resistance, but in vitro data suggests that newly
introduced fluoroquinolones may be effective when resistance to previous generation
fluoroquinolones is present (cross resistance within earlier quinolones, such as
ciprofloxacin and ofloxacin, is very high) (23, 24). Kanamycin and amikacin have
almost 100% cross resistance (23, 24). Streptomycin is believed to have low levels of
cross resistance with kanamycin and amikacin (23, 25).

Emergence of Multidrug Resistant Tuberculosis
Multidrug-resistant tuberculosis (MDR-TB), defined as resistance to at least
isoniazid and rifampicin (the two most important first-line drugs), appeared after the
introduction of rifampicin in 1966. Unit 1990, however, most MDR cases occurred in
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patients receiving prolonged, inappropriate therapy; while sporadic outbreaks of primary
transmission occurred, the magnitude and impact was relatively limited (26). In the early
1990’s, several large outbreaks of MDR-TB unfolded in hospitals and institutions in the
United States, announcing MDR-TB as a major public health threat (27-30). In New
York City, where the largest number of MDR-TB cases were reported, as many as one in
five TB cases involved MDR (28). Strong evidence of recent, primary transmission of
resistant TB was established. Among patients who had never been treated before, 23%
were resistant to one or more drugs (28). Molecular fingerprinting by restriction
fragment length polymorphism (RFLP) implicated a single strain in 22% of MDR cases
in New York City in 1992 (31). High rates of nosocomial transmission, to health care
workers and HIV positive patients in particular, were documented (27, 29). Together,
these circumstances demonstrated the rapidity with which MDR-TB could spread through
susceptible populations. Through a massive investment of human and financial resources
(estimated by some to be as high as a billion dollars), the MDR-TB epidemics in New
York and elsewhere in the country were brought under control and the incidence of
MDR-TB plummeted (32). Subsequent nosocomial and institutional outbreaks in Italy,
Spain, Russia and Chile made it clear that MDR-TB ranked among the most serious
public health issues facing the world (33-36).
Global data on the prevalence of MDR-TB, however, were lacking. The first
global survey of TB drug resistance was published in 1997 by the Global Project on AntiTB Drug Resistance, a collaboration between the World Health Organization and the
International Union Against Tuberculosis and Lung Disease. Two subsequent global
surveys, covering the periods of 1996 to 1999 and 1999 to 2002, further elucidated the
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worldwide picture of drug resistance (37). The most recent data published by the Global
Project revealed that virtually all countries surveyed reported TB drug resistance and
estimated that 424,000 cases of MDR-TB emerged in 2004 (38). With the exception of
Botswana, which was found to have rising rates of MDR-TB, no trend data was available
from Africa, a result of the poor laboratory infrastructure and surveillance on the
continent. Twenty sites worldwide reported drug resistant TB prevalence in excess of
20%, and eleven sites reported rates of MDR-TB among new cases of over 6.5%. The
geographic distribution of MDR-TB is highly uneven and ranges from 0.7% in new cases
in established market economies, to around 2% in Africa, Southeast Asia and South
America, and over 10% in some areas of the former Soviet Union and several provinces
in China. Among previously treated cases, the rate of MDR is often several fold higher;
by 2002, nine settings had been identified as having MDR rates of above 30% in
previously treated cases.
More recently, the emergence of extensively drug resistant tuberculosis (XDRTB), defined as TB resistant to isoniazid, rifampicin, quinolones and at least one of three
injectable second line drugs (kanamycin, capreomycin, or amikacin), in every region of
the world has raised further alarms about the future of TB control (see “The ‘Tugela
Ferry Outbreak’ of Extensively Drug Resistant Tuberculosis,” below) (39-41). A review
of global DST data conducted by researchers at the CDC found 347 isolates of XDR-TB
worldwide, accounting for 2% of all TB isolates surveyed and 15% of MDR-TB isolates;
data from African and Asian countries, other than South Korea, were notably lacking
(39). In early 2005, the first reports emerged of an outbreak of XDR-TB at a hospital in
rural KwaZulu Natal, South Africa, confirming fears about the rise of drug resistant TB
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in high HIV prevalence settings (see “The ‘Tugela Ferry Outbreak’ of Extensively Drug
Resistant Tuberculosis,” below) (41).
There is tremendous concern among public health practitioners that the rise of
drug resistant tuberculosis will undermine the success of extent TB DOTS programs and
worldwide TB control. The ability of DOTS programs to reduce transmission and
incidence of both drug susceptible and drug-resistant tuberculosis is debatable; while
some studies have shown successful reduction of drug resistance under the WHO strategy
(42), others have demonstrated an “amplifier effect” of increasing drug resistance under
DOTS-prescribed short-course chemotherapy (43-46). One study of patients receiving
short course chemotherapy in a penitentiary hospital in Siberia found that over 3% of
patients completing treatment, and over twenty percent of patients who began treatment
with an isolate resistant to three first-line drugs, had amplified resistance over the course
of therapy (47). Large scale epidemiological data is presently lacking, but mathematical
models have suggested that MDR-TB hotspots could evolve in areas with successful
DOTS programs due to the amplifier effect (48).
Treatment of multidrug-resistant tuberculosis with second line drugs is much
more expensive and requires a longer duration of therapy. As such, it became a
contentious public health issue in the past decade, pitting moral and cost-effectiveness
arguments against each other in debates about global health resource allocation (49).
Prior to 1999, the prices of second line drugs were exorbitantly high and no global
mechanism existed for coordinating supply, negotiating drug prices, financing programs,
setting treatment guidelines and standards, and overseeing program performance (50). In
1999, the WHO and its partners launched a “DOTS-Plus for MDR-TB” initiative,
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followed by the “Green Light Committee” (GLC) a year later (51). Together, these
bodies have increased access to second line drugs in resource poor settings and ensured
that treatment of MDR-TB supplements, rather than detracts from, the success and
resources of existing TB DOTS programs. Despite the success that the DOTS Plus
initiative and GLC have had in scaling up MDR-TB treatment in resource poor countries,
only 10,000 patients, or less than 5% of the world’s total cases, are currently receiving
second line drugs (SLD) through this mechanism (24). The overwhelming majority of
patients afflicted with MDR-TB in developing countries remain without access to second
line drugs.

Multidrug-Resistant Tuberculosis in South Africa
Tuberculosis drug resistance surveillance throughout Africa has been extremely
relatively limited due to poor public health infrastructure and the paucity of laboratories
with capacity to perform drug susceptibility testing (DST); nevertheless, the existing data
suggest that African countries have some of the lowest rates of multidrug-resistant
tuberculosis of developing countries. Reasons for this include the relatively recent
introduction of rifampicin into the public sector and delays in drug resistance surveillance
and reporting amidst volatile HIV and TB epidemics (52).
Compared with most Sub-Saharan African countries, South Africa has an
advanced public health infrastructure and far greater capacity for drug resistance
surveillance. Between 1965 and 1991, twenty-five annual surveys of drug resistance
were carried out by the Tuberculosis Research Institute of the South African Medical
Research Council (53). The results of these surveys found a dramatic decline in
prevalence of both primary and acquired drug resistant tuberculosis. In 1995, the
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Medical Research Council’s TB research programme was suspended due to budgetary
constraints. Several smaller drug resistance surveys, including two provincial surveys,
were undertaken, but national data were not collected again until 2001. The data from
these interim surveys suggested that the prevalence of MDR-TB remained low in the
mid-1990s but began to rise in the latter half of the decade (50, 54-57).
The most recent national estimates of tuberculosis drug resistance in South Africa
were based upon a survey covering nine provinces of the country and carried out between
2001 and 2002 by the Tuberculosis Lead Programme of the Medical Research Council in
South Africa, which is part of the Global Network of Supranational Reference
Laboratories for Drug Resistance Surveillance of the World Health Organization (58).
Nationwide, any drug resistance was detected in 7.8% of isolates from new patients and
15.5% of isolate from retreatment cases. MDR prevalence was 1.6% among new cases
and 6.6% among retreatment cases. A quarter of all MDR cases had resistance to all four
first line drugs against which they were tested (isoniazid, rifampicin, ethambutol, and
streptomycin). In KwaZulu Natal (KZN), the prevalence of MDR-TB among new
patients and retreatment patients were marginally higher than the national average at
1.7% and 7.7%, respectively. The prevalence of HIV among pan-susceptible, any
resistance and MDR patients were 63.2%, 76.1% and 76.9%. The survey in KZN
suffered from the failure of most districts to submit an adequate number of specimens;
only two of the eight districts met the sample number targets, and five of the eight
districts reported less than 70% of the targeted number of specimens. DST for second
line drugs was not performed in this survey.

11

Though the rates of MDR-TB among new and previously treated cases were
relatively low compared with some areas of Eastern Europe, Central Asia and Russia, the
absolute number of TB patients in South Africa is so high that the burden of MDR-TB is
enormous. In KZN alone, the estimated number of new MDR cases per year, by these
rates, was 1385 to 2616—ten to twenty times the total number of cases of MDR-TB in
the entire United States in 2005 (58, 59). The declining case identification and treatment
success rates in South Africa in recent years make the rise of drug resistant tuberculosis a
likely and concerning possibility (2). A recent survey of drug resistance at one hospital
in KZN found an MDR-TB rate of 39% among sputum culture positive cases (41).
Notably, the district in which this hospital lies was not included in the drug resistance
surveillance study of 2000-2002, suggesting that the survey may have failed to identify
significant MDR hotspots.

‘The Tugela Ferry Outbreak’ of Extensively Drug Resistant Tuberculosis
In early 2005, researchers from a joint U.S.-South African team conducting a
prospective trial of HIV and TB treatment integration at a rural hospital in Tugela Ferry,
KwaZulu Natal, South Africa, noted higher than anticipated rates of mortality in their
cohort of subjects receiving antiretroviral therapy concomitant with antituberculosis
therapy (41). Further investigation revealed that six of the 119 patients co-infected with
HIV and TB were infected with M. tuberculosis that was resistant to all six drugs against
which it was tested: isoniazid, rifampicin, ethambutol, streptomycin, ciprofloxacin, and
kanamycin. Increased surveillance undertaken as a result of these findings revealed that
between the period of January 2005 and March 2006, 53 patients presenting to the
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hospital were infected with organisms showing this same pattern of resistance to six
drugs, meeting the WHO’s new criteria for XDR-TB (60). Mortality was exceptionally
high (98%), with the median survival from the time of sputum collection being just 16
days. All patients for whom HIV status was known (83%) were positive. The majority
(55%) of patients had never received previous treatment for tuberculosis and only 15%
had failed or defaulted therapy. Genotyping of 46 of the isolates revealed that 39 (85%)
were genetically similar. These findings, taken together, were considered evidence of
primary drug resistance with recent transmission, and the high proportion of patients who
were hospitalized in the past year was suggestive of nosocomial transmission. Further
concerning was the high prevalence of MDR-TB (39%) among culture positive cases, a
figure far higher than that found by a province-wide tuberculosis resistance survey
undertaken three years prior (58).
The results of this investigation, presented in August of 2006 at the International
AIDS Conference, provoked alarm in the public health community. The findings in
Tugela Ferry represented one of the first instances of the recognition of large number of
cases of highly drug resistant tuberculosis in a high HIV-prevalence setting; additional
laboratory data from the provincial diagnostic mycobacteriology laboratory revealed that
XDR-TB isolates had been found in 28 hospitals across the province. The World Health
Organization, in collaboration with the South African Medical Research Council and U.S.
Centers for Disease Control, responded by convening an expert consultation on XDR-TB
in Johannesburg in September, followed by the first meeting of the Global Task Force on
XDR-TB in Geneva in October, 2006 (61). The WHO Global Task Force on XDR-TB
revised the definition of XDR-TB and promulgated recommendations for its prevention
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and control (62). According to the revised definition of XDR-TB, the total number of
XDR cases identified at this single hospital between January 2005 and December 2006
was over 200.

Clinical Issues in Drug Resistant Tuberculosis
Laboratory and Clinical Diagnosis
Drug susceptibility testing (DST) is the principal strategy for establishing the
resistance pattern of tuberculosis to antituberculosis chemotherapeutic agents. The
classic approach to DST involves inoculation of a solid media (e.g. Lowenstein-Jensen,
7H10 or 7H11 agar) impregnated with a tuberculosis drug in a defined concentration with
either a concentrated specimen (direct method) or pure culture (indirect method) and then
assessing growth by one of several methods: the proportions method, the absoluteconcentration method, or the resistance-ratio method (63). According to the proportions
method, a resistant isolate is one in which the number of colonies growing on the drugimpregnated plate is greater than or equal to 1% of the number of colonies on a non-drug
impregnated plate (direct comparison between plates for colonies can be made by
increasing the concentration of the isolate on the impregnated plate by 100 fold).
Additional methods include the BACTEC-460, an automated liquid medium
system that assesses mycobacterial growth by detecting the consumption of radioactive
(14C) mycolic acids through measuring the release of 14CO2 (63). More recently, a
nonradioactive automated BACTEC-960 system has shown promise as an alternative for
mycobacterial culture and DST in advanced laboratories. These systems are more rapid
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but are expensive and require a laboratory infrastructure far beyond that available in
many resource poor settings.
Molecular approaches for identifying drug resistant M. tuberculosis, including
rapid genetic tests, are currently in use in many laboratories and are gaining interest for
their speed and potential for use in areas with limited laboratory capability. The most
commonly used tests assay for the rpoB gene associated with rifampicin resistance (11).
Several large studies are currently underway to evaluate the use of rapid rifampicin tests
in resource-limited settings. Finally, the recent demonstration of a rapid, low cost
technique for culture and susceptibility known as “Microscopic Observation of Drug
Susceptibility” (MODS) has generated considerable excitement about the potential for
cheap and rapid culture and DST, particularly in resource limited settings. In
demonstration and operational studies in Peru, MODS was shown to be highly sensitive
and specific, cost a fraction of existing culture and DST methods, and provide results in
half the time of BACTEC and less than a fifth the time of conventional LowensteinJensen agar with the proportion method (64). However, the sensitivity and specificity of
this method for identifying resistance to SLDs has not been studied, and biosafety
concerns still present a major obstacle to the rapid introduction of this test into resource
limited environments.
Criteria for drug resistance testing for most SLDs (excluding more recently
introduced drugs, such as quinolones) were established nearly 50 years ago; nevertheless,
their validity in terms of correlation with in vivo outcomes has recently come into
question (65). DST for SLD is considered to be more complicated, in part because
critical drug concentrations defining resistance are not as close to the minimal inhibitory
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concentrations for SLDs as they are for first-line drugs (66). Furthermore, proficiency
metrics, such as those obtained for first-line drug susceptibility testing, are unavailable
for most SLDs (though proficiency testing exercises among supranational reference
laboratories is underway).
In the vast majority of clinical settings in the developing world, where most cases
of tuberculosis occur, DST for first or second line drugs is not routinely performed. Even
in areas where DST is available, routine use in all newly diagnosed patients is often
infeasible due to costs or the limited sample processing capacity of laboratories. Further,
the existing methodologies require 2-3 months for diagnosis. As such, the clinical history
plays a large part in diagnosing probable drug resistance and targeting DST. Risk factors
for drug resistant tuberculosis include: failure of short-course chemotherapy (SCC),
known exposure to an MDR-TB case, known exposure to a patient who died while taking
SCC, relapse after default, non-adherence to SCC, co-morbid conditions associated with
malabsorption, and residence in areas (or institutions) of high MDR-TB prevalence (11).
The role of outcomes from previous TB treatment in predicting drug resistant TB is
significant yet not fully characterized; the prevalence of TB and of drug resistant TB in
the population, as well as the immune status of the patient, probably impact considerably
the predictive value of this factor. In several case control studies assessing risk factors
for drug resistant tuberculosis, the increased risk associated with previous TB treatment
ranges from two fold to more than ten fold (67-74). However, little data from Africa or
high HIV prevalence settings is available.
In patients who are receiving therapy, those who remain or become sputum
positive at 4 months, have persistent fevers, or have worsening clinical or radiological

16

parameters should provoke a high suspicion for drug resistance. To date, however, there
are no reliable clinical algorithms for accurately predicting drug resistant tuberculosis
(52).

Fitness and Transmissibility
The debate surrounding the relative virulence or fitness of drug resistant strains
compared with drug sensitive strains is an unresolved one. Early animal models
suggested that the development of drug resistance may be associated with a loss of
virulence factors, such as catalase activity, by bacilli (75, 76). Subsequent
epidemiological studies, looking at cluster development of drug resistant versus drug
susceptible cases and the differential development of secondary cases among contacts,
affirmed this hypothesis by showing lower infection rates among groups exposed to drug
resistant TB (77, 78). However, other studies, including those of the “strain W”
responsible for much of the New York City outbreak in the 1990s, have found drug
resistant TB to be at least as virulent and transmissible (79, 80); “strain W”, in particular,
was shown to be catalase positive. In all likelihood, there is heterogenecity in virulence
among strains of drug resistant TB.
Whether or not drug resistant tuberculosis is less fit or transmissible, cases of
MDR-TB are likely to generate more secondary cases due to the prolonged infectious
period associated with delayed identification, inadequate treatment, longer time to culture
conversion once on SLD, and lower cure rates. Moreover, mathematical models suggest
that, even where strains of MDR-TB are less fit than pan-susceptible strains, hot zones of
MDR-TB can develop, largely as a result of low cure rates and amplification probabilities
(48).
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HIV and TB Drug Resistance
The associations between HIV infection and the development of multi-drug
resistant tuberculosis have not yet been fully clarified. Among the most important
unresolved questions is whether HIV infection is an independent risk factor for the
development of multi-drug resistant tuberculosis. Several studies have shown increased
rates of drug resistant TB among HIV infected individuals (81-83), while other data,
including the results of the Global Anti-TB Drug Resistance surveys, have failed to
confirm this finding (37, 56, 84-86). Higher rates of drug resistant TB found in the
smaller studies could, in part, be due to the fact that recently circulating strains are more
likely to be drug resistant, and HIV-infected patients manifest TB disease more rapidly,
such that they are disproportionately represented in the early stages of outbreaks of drug
resistant TB.
While the population-level impact of HIV on drug resistance remains to be
established, several clinical observations have been studied concerning the relationship
between HIV disease and the development of drug resistance. Patients with HIV have
been observed to have higher rates of rifampicin monoresistance, further associated with
diarrhea, prior rifabutin use (e.g. for MAI treatment/prophylaxis), positive AFB smear,
nonadherence to therapy, severe immunosuppression, and antifungal therapy (22, 87).
Patients co-infected with HIV have varying degrees of intestinal absorption of TB drugs
(88-90) and of treatment failure with standard regimens (91-93) both potentially
increasing the risk of acquiring or amplifying TB drug resistance.
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In addition to its role as a determinant or co-determinant of drug resistance, HIV
disease and its management have clinical implications for the diagnosis and treatment of
MDR-TB. HIV-infected individuals undergoing treatment for MDR-TB have lower rates
of treatment success and higher mortality than uninfected patients (94, 95). Diagnosis of
any form of TB, including MDR-TB, is more challenging in the presence of HIV disease,
in that sputum smear and radiographic findings are less sensitive and extrapulmonary
disease is more common than in uninfected patients (96-102). Certain second line drugs
are more toxic in patients infected with HIV, while the use of antiretrovirals
concomitantly with SLDs may result in problematic drug-drug interactions (11, 24).
Finally, regardless of whether HIV is an independent risk factor for the
development of MDR-TB at the individual level, the increased pool of susceptible
patients who serve as both hosts and vectors for all forms of TB, including MDR-TB, is
certain to increase the absolute burden of MDR-TB at a population level. Moreover, at a
programmatic level, the HIV epidemic, particularly in Africa, has overwhelmed and
disrupted the established TB control programs, causing rising treatment failure rates and
increasing the opportunity for drug resistant TB to emerge and spread.

Treatment of MDR-TB
Compared with therapy for drug susceptible tuberculosis, treatment of MDR-TB
requires a longer duration, is considerably more complicated, expensive, and toxic, and
treatment success rates are typically lower. Various treatment strategies have been
employed, including the use of standardized treatment regimens based upon
representative local susceptibility patterns, empirical treatment based upon previous
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treatment history and local DST patterns, and individualized treatment designed on the
basis of individual DST results (24). It is recommended that regimens include at least
four drugs that are certain, or expected, to be effective and that the duration be a
minimum of 18 months beyond sputum conversion. Injectable agents should be used for
a minimum of 6 months.
Management of patients receiving second line drugs requires fairly intensive
monitoring for drug toxicities and treatment failure. While some cohorts have found high
rates of treatment interruption due to side effects and toxicities, well designed programs
have demonstrated that, in spite of the high frequency of adverse effects, life-threatening
adverse events are uncommon and management in resource limited settings can be done
successfully (103-105). Sputum culture conversion typically occurs between one to two
months after the initiation of therapy, while smear conversion may take longer as it does
not distinguish between viable and nonviable organisms (106). Patients who have
persistently positive sputum smears or cultures after three months of therapy with SLD
should raise concerns for either poor adherence or improper regimen choice, and further
evaluation including DST may be indicated (11).
Treatment outcomes among MDR-TB cases have varied widely; a recent survey
of five GLC-approved sites in resource-limited countries found treatment success rates of
70% (107). A number of factors have been associated with treatment failure and death.
In the aforementioned survey of GLC-approved sites in resource-limited countries,
treatment success and death rates were 77% and 3.5%, respectively, in new cases and
68.5% and 14% in previously treated cases. Patients infected with HIV have consistently
been found to have higher rates of mortality during MDR-TB treatment than HIV
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uninfected individuals (94, 108). One case series in South Africa found MDR-TB
treatment success rates of 38% in HIV infected individuals, compared with 47% in those
who were uninfected (109). In another cohort in Peru, low baseline hematocrit and body
mass index were each independently associated with decreased time to death, while the
inclusion of pyrazinamide and ethambutol in the regimen (in patients with DSTdocumented susceptible organisms) was independently associated with favorable
treatment outcomes (106). A review of MDR-TB treatment outcomes in Latvia found
treatment success of 76% among HIV uninfected patients and of 56% among infected
patients; resistance to ofloxacin was independently associated with a much slower time to
culture conversion and an increased risk of poor outcomes (110).
At a programmatic level, the World Health Organization recommends that
treatment of multidrug-resistant tuberculosis be based upon principles closely related to
those of its general DOTS strategy for TB control: sustained political commitment; a
rational case-finding strategy including accurate, timely diagnosis through qualityassured culture and DST; appropriate treatment strategies that use second-line drugs
under proper case management conditions; uninterrupted supply of quality-assured
antituberculosis drugs; standardized recording and reporting system (24). While these
components can be expensive and require substantial investment of human and laboratory
resources, the experience from multiple countries is that addressing drug resistant
tuberculosis strengthens, rather than detracts from, national tuberculosis programmes.
Moreover, data from Peru suggests that treatment of MDR-TB is cost-effective (111). To
date, however, DOTS Plus for MDR has not been implemented on a large scale in Africa,
and data on outcomes from the region are limited.
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Need for Rapid Identification of MDR and XDR-TB Patients
The timely identification of patients with MDR-TB and XDR-TB is challenging
and yet has significant implications on the outcomes for individual patients and their
potential for spread to others. Among the first 53 patient reported with XDR-TB in
Tugela Ferry, the median survival from the time of sputum collection was 16 days;
however, the results of sputum culture and DST by conventional methods (as are
available KwaZulu-Natal) typically takes three to six weeks, meaning most patients had
died before their diagnosis of XDR-TB was made. Moreover, many patients are
hospitalized while awaiting sputum culture and DST results; in Tugela Ferry, patients
with unknown TB resistance patterns share a single, large room with approximately 40
other patients. Such circumstances make nosocomial transmission of drug resistant
tuberculosis highly probable.
While the introduction of rapid culture and DST techniques is needed in this
setting, the requisite infrastructure and resources are not yet available. As such, there is
an urgent need for the further elucidation of the clinical characteristics of MDR-TB and
XDR-TB patients and the identification of clinical predictors of drug resistant TB. Such
information may facilitate the early identification of patients with MDR-TB and XDRTB, hopefully leading to improved treatment outcomes and reducing community and
nosocomial transmission. In settings without access or with limited access to DST,
which include most of the developing world, clinical assessment of TB for drug
resistance is the primary tool for diagnosis, making the development of clinical predictors
of drug resistant TB particularly needed.
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METHODS
Setting
This study was carried out at the Church of Scotland Hospital (COSH), a 360 bed
provincial government district hospital in the Msinga subdistrict of KwaZulu Natal,
South Africa, a rural region of approximately 2000 km2. COSH provides medical
services to a catchment population of approximately 250,000 Zulu people, living in
traditional family compounds dispersed widely through areas with few roads, poor
transportation infrastructure, sparse electricity and a dearth of potable water.
Unemployment rates are estimated to be in excess of 60%. The prevalence of HIV
infection among inpatients and women presenting to the maternity ward are 40% and
20%, respectively. There are ten full-time physicians working at the hospital at any given
time, and laboratory infrastructure exists for sputum microscopy for acid-fast bacilli but
no culture or other microbiological tests.
At present, there are four TB wards: two general TB wards (one male, one
female), each containing approximately 35 beds; and two TB “isolation” wards (one
male, one female), each containing 10 beds. The male isolation ward is a separate
building, whereas the female isolation ward is a partitioned room of the female TB ward
that has no door and an open airflow with the general female TB ward. Both wards are
almost always over capacity, forcing a number of patients to sleep on the floor. In
addition there is one male and one female internal medicine ward, a surgical ward,
pediatrics ward, and obstetrics wards. HIV testing us offered to all patients with TB, and
around 70% of patients accept testing.
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COSH has been a site for a government-sponsored TB DOTS program since
1993. Diagnosis is made by sputum microscopy, x-ray, and/or clinical criteria, according
to the South African National Tuberculosis Guidelines (112). Each year, approximately
1800 cases of tuberculosis are diagnosed and managed by COSH and its surrounding
satellite clinics. All patients receive free directly observed therapy, administered at home
by community health workers or in nearby clinics. A standard regimen is used,
consisting of isoniazid, rifampicin, ethambutol and pyrazinamide for a two month
intensive phase, followed by a 4-month continuation phase with isoniazid and rifampicin.
These are given as fixed dose combination pills containing 4 drugs (intensive phase) or 2
drugs (continuation phase), reducing pill burden. Since June 2005, sputum samples for
all patients with signs and symptoms of tuberculosis have been collected and sent for
culture and drug susceptibility testing at the provincial diagnostic mycobacteriology
laboratory in Durban. Results are transmitted back to COSH via paper copies once
weekly and are also available to COSH staff on an intranet-based laboratory reporting
system. The details of the culturing and drug susceptibility testing methods are described
in the “Mycobacterial Culture and Drug Susceptibility Testing Methods” section.

Study Design
This was a retrospective, case-control control study of patients diagnosed with
tuberculosis at a rural hospital in KwaZulu Natal, South Africa. This site was chosen due
to the recognition of an outbreak of XDR-TB in 2005 (see INTRODUCTION). The primary
objective of the study was to identify clinical predictors of tuberculosis drug resistance
and mortality among this population. The study was designed as a case-control study
comparing three groups of patients: patients with XDR-TB, patients with MDR-TB but
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not XDR-TB, and patients with non-MDR-TB. Cases were defined according to drug
susceptibility testing of sputum cultures, described below. XDR-TB was defined as
resistance to at least isoniazid, rifampicin, ciprofloxacin and kanamycin. Ciprofloxacin
and Kanamycin were the only second line drugs against which M. tuberculosis is
currently tested at the referral laboratory for COSH, the provincial diagnostic
mycobacteriology laboratory at the Inkosi Albert Lathuli Central Hospital (See
Mycobacterial Culture and Drug Susceptibility Testing Methods below). MDR-TB
was defined as resistance to at least isoniazid and rifampicin. Non-MDR-TB was defined
as susceptibility to either rifampin or isoniazid or both (irrespective of susceptibility to
other drugs). While XDR-TB is a subgroup of the category of MDR-TB (all XDR
isolates must have resistance to isoniazid and rifampicin), the MDR-TB group in this
paper refers to patients who had only MDR-TB and did not meet the criteria for XDRTB.
The study period was from June 1, 2005 through August 31, 2006. The starting
point of this period was selected because from this point forward, the hospital adopted a
policy whereby sputum samples for culture and drug susceptibility testing were collected
for all patients suspected of having tuberculosis. This reduced bias in patients having
sputum cultures, in that, rather than targeting patients suspected of failing treatment for
DST, clinicians sought to acquire DST for all patients.
The primary outcomes of interest were risk factors for MDR-TB and XDR-TB.
Secondary outcomes were risk factors for death. Variables or factors examined included
demography, treatment outcomes, mortality, HIV status, number and duration and timing
of hospitalizations prior to and subsequent to treatment, time elapsed between initiation
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of treatment and death, time elapsed between treatment initiation and DST, time elapsed
between DST and death, use of second line drugs, recorded symptoms, weight changes,
use of antiretroviral therapy, CD4 count, laboratory results (hemoglobin and ESR) at
diagnosis and on therapy, and sputum smear and culture results.

Selection of Subjects
Selection of subjects for inclusion in the study was carried out in the following
way. First, a list of patients with MDR and XDR-TB was compiled based upon a registry
kept and maintained by the staff at COSH. Charts were obtained from the hospital’s TB
DOTS office and the hospital’s central file storage room. All patients diagnosed by
sputum drug susceptibility testing as having MDR or XDR-TB between the period of
June 1, 2005 and August 31, 2006 for whom charts could be located were included.
Patients who were diagnosed with TB before June 1, 2005 were excluded because prior
to this date, sputum for culture and DST were only targeted at patients with treatment
failure. Since June 1, 2005, the hospital policy has been to obtain sputum for culture and
DST on all newly diagnosed TB patients.
Once review of charts was completed, patients whose current episode of TB was
diagnosed and treatment initiated before June 1, 2005 were excluded from the study.
These were patients who began treatment prior to June 1, 2005 but whose diagnostic
sputum culture was collected after June 1, 2005. This excluded 13 patients with XDRTB and 10 patients with MDR-TB, leaving 52 patients in the MDR-TB group and 61
patients in the XDR-TB group.
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The control group of non-MDR patients was compiled by reviewing the TB
DOTS registry, which contains all patients diagnosed with tuberculosis at COSH, and by
cross-checking with the Kwazulu-Natal Department of Health laboratory server. All
patients diagnosed with TB at COSH after June 1, 2005 were eligible for inclusion. The
first 60 patients with a positive sputum culture, a non-MDR-TB first resistance pattern,
and an available medical chart were entered into the study. Three patients were later
excluded due to the absence of chart information, leaving 57 patients in the non-MDRTB group.

Classification of Patients with Multiple Resistance Patterns
Many patients had two or more M. tuberculosis isolates with different drug
susceptibility patterns, some of which fell in two or more different drug resistance
groups. For comparative purposes, it was necessary to group patients according to drug
susceptibility pattern, but to do so in a cross-sectional manner, without assigning patients
to multiple groups. This presented a challenge in categorizing these patients into drug
resistance groups without biasing the groups. For example, if the highest level of
resistance was used to classify patients, then all patients who had a pan-susceptible
sputum first and then developed MDR-TB or XDR-TB would be classified in the latter
two groups; when analyzing the outcomes of the pan-susceptible group, it would appear
as though no patients went on to develop MDR-TB or XDR-TB. If the first sample found
in the time period under examination was used to classify patients, no patients with
MDR-TB or XDR-TB could have a prior non-MDR-TB sample, which would obscure
acquired and transmitted resistance.
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To address this problem and minimize biases in clinical predictors and outcomes,
patients who had two or more M. tuberculosis isolates with different drug susceptibility
patterns were treated in the following manner during subject selection.
For all groups, if the differing isolates were collected within three days of one
another, the patient was grouped according to the highest level of drug resistance. For
example, if sputum samples from one day showed an isolate with pan-susceptible
tuberculosis and another isolate within 3 days had XDR-TB, the patient was placed in the
XDR-TB group.
For the creation of the MDR and XDR groups, if the isolates with differing DST
patterns were collected on separate days more than 3 days apart, the patient was grouped
according to the highest level of resistance found.
The creation of the non-MDR-TB group was done systematically through the
review of DOTS registers, so the first (non-MDR) sputum found was used to classify
patients. If these patients went on to develop MDR-TB or XDR-TB, they were
nevertheless kept in the non-MDR-TB group, because the development of MDR-TB or
XDR-TB in these patients was considered an important outcome.
Finally, patients who were first classified into the MDR and XDR TB groups but
who were selected randomly through the TB register as non-MDR-TB patients were
moved to the non-MDR-TB group.
Patients who had multiple susceptibility patterns were included in the bivariate
and multivariate analyses to examine clinical predictors and outcomes and were also
examined separately as a case series.
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Data Collection
There were five sources of data utilized in this study: the TB DOTS register; the
hospital medical record; laboratory data stored on the Department of Health’s server and
accessible through an intranet; the registry of MDR and XDR-TB patients in the TB
DOTS clinics; and spreadsheets maintained by the COSH ARV Clinic.
The TB DOTS register contained treatment category (new patient, retreatment
after cure, re-treatment after interruption, etc), treatment regimen, sputum smear
information at 0, 2 and 6 months, and treatment outcomes (cure, treatment completion,
treatment interruption, transferred out, death).
The patient’s hospital medical record contained the majority of information,
including demographics, HIV status, clinical and laboratory details from outpatient visits
and hospitalizations, previous episodes of tuberculosis, date of transfer to a tertiary
facility for second line drugs, and death certificate. The registry of MDR and XDR-TB
patients maintained in the TB DOTS clinic contained information on the tracing of
patients found to have MDR and XDR-TB, including whether the patient was alive or
deceased at the time of tracing. Spreadsheets maintained by the COSH ARV Clinic
contained antiretroviral therapy related information including CD4 counts, viral loads,
and date of initiation of therapy.
Data collection from each of these sources was performed by the author and
entered directly onto a standardized electronic data collection form linked to a Microsoft
Access 2002 (Microsoft Corp, Redmond, WA, USA) database created by the author and a
co-investigator (NRG). Data collected concluded on November 15, 2006; mortality and
other outcomes were included up until this date. For patients who were not confirmed to
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have died, the survival or observation period was taken to conclude at the last point in
which the patient was documented to have visited the hospital or clinic.

Mycobacterial Culture and Drug Susceptibility Testing Methods
Sputum samples were obtained from all patients for mycobacterial culture and
drug susceptibility testing as part of routine clinical care and disease surveillance at
COSH. Some of the sputa were collected at the time of TB diagnosis as directed by
hospital procedures during this time; others were collected after the initiation of therapy,
either due to suspected treatment failure or the lack of sputum collection at the time of
diagnosis. The sputum collection, culture, and drug susceptibility testing methods have
been previously described and published (41):

Typically, one to three samples were taken per patient. The samples were
not induced and were taken at any time of day. Sputum specimens were stored at
4°C for up to 3 days until transport to the provincial diagnostic mycobacteriology
laboratory in Durban. Digestion and decontamination was done with the N-acetylL-cysteine-sodium hydroxide method. An auramine-stained smear was made and
the remaining deposit was inoculated in one mycobacteria growth indicator tube
(MGIT) broth and on one Middlebrook 7H10 agar plate. The broths were
incubated at 37°C in an automated incubator. Agar plates were sealed in CO2permeable plastic bags and incubated in 5% CO2 at 37°C. Acid-fast microscopy
was done on each positive MGIT broth when a positive reading was obtained.
Those containing acid-fast bacilli were subcultured on Middlebrook 7H10 agar.
Primary Middlebrook agar plates were read weekly for 3 weeks or until growth
was observed. Microscopy was done to confirm the presence of acid-fast bacilli.
All positive cultures were identified as Mycobacterium tuberculosis by means of
niacin and nitrate reductase tests. The risk of cross-contamination was minimized
by processing samples individually in real time, rather than batching. Quality
assurance was done weekly by the UK National External Quality Assessment
Service programme, where ten consecutive isolates were fingerprinted to rule out
cross-contamination. Susceptibility tests were done on all isolates using the 1%
proportional method on Middlebrook 7H10 agar. All isolates were tested for
susceptibility to isoniazid (1 mg/L), rifampicin (2 mg/L), ethambutol (5 mg/L),
streptomycin (2 mg/L), kanamycin (16 mg/L) and ciprofloxacin (2 mg/L).
Susceptibility testing to pyrazinamide and the remaining four classes of second
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line drugs—ethionamide, cycloserine, capreomycin, and para-aminosalicylic
acid—are not routinely done.
Statistical Analysis
Bivariate analyses were undertaken to compare clinical characteristics between
drug resistance groups and identify significant associations with mortality among all drug
resistance groups. T tests and Wilcoxon tests were used to compare means and medians,
respectively, and all dichotomous and nominal data were analyzed by Chi-square analysis
and Fischer’s exact tests. Kaplan-Meier survival curves were produced to express
differences in survival between drug resistance groups. Comparisons in each analysis
were made between 2 of the 3 groups at a time: non-MDR vs. MDR, MDR vs XDR, and
non-MDR vs. XDR.
Multivariate logistic regression was used to determine factors independently
associated with drug resistance. Similar to the bivariate analysis, comparisons were made
between 2 of the 3 drug-resistance groups at a time. Independent factors tested were:
age, sex, CD4 cell count, hospitalization in the previous 2 years, TB treatment in the
previous year, and sputum smear. Cox proportional hazards modeling was used to assess
factors independently associated with mortality. Independent factors tested included:
age, sex, CD4 cell count less than 50, CD4 cell count less than 200, MDR-TB, nonMDR-TB, XDR-TB, TB treatment in the previous year, and hospitalization in the
previous year. A subset of patients who had changes in resistance patterns over the
survey period were analyzed separately and descriptively as a case series. All analysis
was performed by the author and a co-investigator (NRG) and done in SAS version 9.1
(SAS Institute Inc, Cary, NC, USA).
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Medicine.
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RESULTS
Demographics and Clinical Characteristics by Drug Resistance Group
Data for 193 patients were reviewed for the study. After excluding patients the
most recent episode of TB was diagnosed and treatment initiated prior to June 1, 2005,
there were 170 patients remaining in the study. Fifty-seven patients were classified into
the non-MDR-TB group, 52 patients were classified into the MDR-TB group, and 61
patients were classified in the XDR-TB group. The demographic information and
baseline clinical characteristics are depicted in Table 1. Of note, women comprised more
than half of the XDR-TB group (55.7%) and less than half of the non-MDR and MDR
groups (40.4%, 34.6%). The difference in sex between the XDR group and the MDR
group was statistically significant (P=0.025). Ages were similar between all three
groups. The median and range of age for the non-MDR, MDR and XDR groups were
32.6 (14.7-70.6), 33.7 (19.9-56.9) and 34.5 (15.4-61.4), respectively.
The sputum smear positive rates were 47.4%, 71.2% and 73.8% for non-MDR,
MDR and XDR patients, respectively. The differences between the non-MDR and MDR
and XDR group were statistically significant (P=0.015, P=0.005). XDR and MDR
patients had slightly higher rates of extrapulmonary TB (29.5%, 30.8%) compared with
non-MDR patients (24.6%), but the differences were not statistically significant (P=
0.469 for MDR versus non-MDR, P=0.546 for XDR versus non-MDR). At baseline,
most patients in all three groups had moderate-severe anemia, with median hemoglobin
in the non-MDR, MDR and XDR groups of 9.0 g/dL, 9.3 g/dL and 9.3 g/dL. Median
erythrocyte sedimentation rate (ESR) was elevated in all three groups and higher in the
non-MDR group (115.5 mm/h) than in the MDR (95 mm/h) and XDR groups (100

33

mm/h), but not significantly so (P=0.187, P=0.272). Median weights were slightly higher
for both men and women in the non-MDR groups (53.0 kg, 52.0 kg) compared with the
MDR only (47.5 kg, 51.0 kg) and XDR groups (49.25 kg, 50.5 kg), but the differences
between all groups were not statistically significant. There were no significant
differences in any groups in terms of reported symptoms of weight loss, cough, night
sweats, or fever.
The HIV-related characteristics of patients by drug resistance group are described
in Table 2. Compared with patients in the MDR group, XDR patients were more likely to
have been tested for HIV (93.4% versus 76.9%, P= 0.012). Among non-MDR patients,
82.5% were tested for HIV, which was not statistically different from the MDR and XDR
groups. The HIV prevalence in the non-MDR, MDR, and XDR groups (among tested
patients) was 93.6%, 92.5%, and 100%, respectively. The differences in HIV prevalence
were not statistically significant. Among individuals co-infected with HIV, 25.0%,
24.3% and 33.3% of patients in the non-MDR, MDR and XDR groups received
antiretrovirals at any time; more patients in the XDR group were on antiretroviral therapy
(ART) at the time of TB diagnosis (14.0%) than in the non-MDR (4.5%) and MDR
groups (5.4%). None of the differences in ART use were statistically significant.
Fewer than half of all HIV infected patients had a viral load performed around the
time of TB diagnosis, and the median log viral load did not differ between the non-MDR,
MDR and XDR groups (5.6, 5.2 and 5.1). Of patients on ART at the time of TB
diagnosis, five patients in the XDR group and none in the MDR and non-MDR groups
had a viral load result. Of the five patients in the XDR group on ART, three had
achieved viral suppression (viral load < 25 copies/mL).
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Among HIV-infected patients, median CD4 cell count at diagnosis (70.5
cells/mm3) was higher in the non-MDR group than in the MDR only (57 cells/mm3) and
XDR groups (56 cells/mm3), but the differences were not statistically significant. When
CD4 counts were stratified into three groups—less than 50 cells/mm3, 50 to 200
cells/mm3, and >200 cells/mm3—the proportion of XDR patients with CD4 cell counts
over 200 (14.3%) was less than that of MDR and non-MDR patients (20.8%, 18.5%), but
not significantly.
Patients in the MDR and XDR groups were more likely than the non-MDR-TB
group to have any previous TB treatment and TB treatment in the past year (Table 3).
Among non-MDR, MDR and XDR patients, 26.3%, 56.9% and 42.6% had been
previously treated for TB. The difference between MDR and non-MDR patients was
statistically significant (P<0.001; OR 4.13, 95%CI 1.84-9.28). MDR-TB patients were
more likely than XDR-TB patients to have had any previous TB treatment, but this
difference did not reach statistical significance. (P=0.072; OR 1.99, 95% CI 0.94-4.21).
However, both MDR and XDR patients were significantly more likely to have had TB
treatment in the past year compared with non-MDR-TB patients (P<0.0001, OR 13.36,
95% CI 2.91-61.39; P<0.001, OR 10.63, 95% CI 2.33-48.48). The difference between
the MDR and XDR groups for TB treatment in the previous year were not statistically
significant (P=0.577).
Compared with non-MDR patients, MDR and XDR patients were significantly
more likely to have had any previous hospitalization (42.3% and 41.0% versus 21.1%;
P=0.017 and P=0.020; OR 2.75 95% CI 1.19-6.38 and OR 2.6 CI 1.15-5.89) and
hospitalization in the past two years (36.5% and 37.7% versus 14.0%; P=0.007 and
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P=0.004; OR 3.53, 95% CI 1.38-9.00 and OR 3.71, 95% CI 1.49-9.20). The proportion
of patients with previous hospitalizations and hospitalizations in the past two years were
similar for MDR and XDR groups.
In multivariable analysis comparing the MDR and non-MDR groups (Table 4),
TB treatment in the previous year was the only significant independent predictor of
MDR-TB (adjusted OR 8.33, 95% CI 1.64-42.33). In multivariable analysis comparing
XDR and non-MDR groups (Table 5), significant independent differences were found for
TB treatment in the past year (adjusted OR 7.19, 95% CI 1.35-38.17) and sputum smear
positive (adjusted OR 2.79, 95% CI 1.20-6.47). Sex was the only significant independent
factor in the multivariable model comparing the XDR and MDR groups (adjusted for
male sex OR 0.41, 95% CI 0.19-0.89) (Table 6). Hospitalization in the past two years
and patient age were not statistically significant risk factors for any of the groupings
under this analysis.

Mortality
The overall mortality rates in the non-MDR, MDR and XDR groups were 36.8%,
73.1% and 85.3%, respectively. Survival by drug resistance group from time of TB
treatment start is depicted by Kaplan-Meier curve in Figure 1. Median survival times for
the non-MDR, MDR and XDR groups under Kaplan-Meier analysis (limiting survival
time among censored to the follow-up period) were 199 days, 103 days, and 92 days,
respectively. The median follow-up period from time of TB diagnosis among surviving
patients was shorter in the non-MDR group (median 52.5 days, interquartile range (IQR)
10-262.5 days) than in the MDR only group (median 119 days, IQR 99-282 days) and
XDR group (median 161 days, 84-181 days). Survival by drug resistance group from
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time of collection of diagnostic sputum (for culture and DST) is shown in Figure 2.
Median survival times for the non-MDR, MDR and XDR groups from sputum collection
were 190 days, 22 days, and 14 days, respectively.
Table 7 shows demographic and baseline clinical characteristics among patients
surviving and those who died. In bivariate analysis, there were no differences in sex or
age between patients who died and those who survived or whose outcome was unknown.
Patients with combined extrapulmonary and pulmonary TB were more likely to die than
those with pulmonary TB alone, though the difference was not statistically significant
(P=0.095, OR 1.88, 95% CI 0.89-3.97); mortality was 75% with patients with
extrapulmonary TB (36/48 patients). Patients who died were more likely to be sputum
smear positive (71.2% versus 50.8%, P=0.007). Median hemoglobin and ESR at baseline
were not significantly different. Median weight at baseline was lower for both men and
women among patients who died, but the differences were not significant (51.0 kg versus
52.0 kg, P=0.40; 48.3 kg versus 53.0 kg, P=0.111).
There was no difference between the proportion of patients tested for HIV
between those who died and survived (85.6%, 83.1%; P=0.662) (Table 8). The HIV
prevalence was slightly higher, but not statistically so, among patients who died (96.8%
versus 93.9%; P=0.409). The proportion of patients on ART at the time of TB diagnosis
did not differ significantly between those who died and those who did not (9.8% versus
6.5%, P=0.522), but the proportion of those who ever received ART was higher in those
who survived (39.1% versus 22.8%, P=0.049). Median log viral load at time of TB
diagnosis did not differ between those who died and survived (5.23 versus 5.28, P=0.82).
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Viral load measurements on ART at the time of TB diagnosis were available for five
patients total; among four who died, two had viral load suppression.
A little over half of patients in both outcome groups had CD4 counts within 120
days of TB diagnosis; median CD4 count was lower in the group who died, but the
difference was not significant (53.5 cells/mm3 versus 104 cell/mm3; P=0.552). Patients
who died were more likely to have a CD4 count less than 50 cells/mm3 (48.1% versus
28.0%, P=0.004) and less than 200cells/mm3 (90.7% versus 64.0%, P=0.004). The odds
ratios of death among patients with <50 cells/mm3 or 50-200 cells/mm3 compared with
>200 cells/mm3 were 6.69 (95% CI 1.69-26.45) and 4.60 (95% CI 1.21-17.52)
respectively.
The relationship between previous TB treatment and previous hospitalization and
mortality is shown in Table 9. The proportion of patients who had ever been treated for
TB did not differ between those who died and survived (44.1% versus 39.0%, P=0.517);
the proportion with treatment in the last year was higher, but not significantly, among
those who died (25.2% versus 13.6%, P=0.076). There was a trend indicating that
patients who died were more likely to have been hospitalized ever (39.6% versus 25.4%,
P=0.064) or in the previous year (27.9% versus 15.3%, P=0.064).
Under the Cox Proportional Hazards model (Table 10), mortality from TB
treatment start was independently and significantly associated with positive sputum
smear (HR 2.09, P=.003), MDR-TB (HR 2.00, P=0.028), XDR-TB (HR 2.50, P=0.002),
and CD4 cell count less than 200 cells/mm3 (HR 3.23, P=0.037). In the Cox model
examining mortality from time of diagnostic sputum collection (Table 11), all of these
associations were greater in magnitude and statistical significance: positive sputum smear
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(HR 2.36, P<0.001); MDR-TB (HR 3.09, P<0.001); XDR-TB (HR 4.31, P<0.0001); and
CD4 cell count less than 200 cells/mm3 (HR 4.69, P=0.006). Patient age, sex,
extrapulmonary tuberculosis, treatment in the previous year, admission in the previous
year, and CD4 cell count less than 50 cells/mm3 all failed to achieve statistical
significance in this model.

Drug Resistance Patterns Among Isolates
Of the 170 patients included in the study, 125 (74%) had a single drugsusceptibility testing (DST) pattern which remained unchanged over their treatment
course. Of the remaining 45 patients, 34 had isolates with two different DST patterns, 10
had three DST patterns, and one had four DST patterns.
A total of 229 isolates with differing DST patterns were cultured from the 170
patients in this study (Table 12). These consisted of 74 non-MDR isolates, 70 MDR
isolates and 85 XDR isolates. Among the 74 non-MDR isolates, 66 (89%) were fully
susceptible, 7 (9%) were mono-resistant (5 to isoniazid (INH), 2 to rifampicin (RIF)), and
one (1%) was poly-resistant (INH and streptomycin (SM)). Among the 70 MDR isolates,
17 (24%) were resistant to only INH and RIF. Resistance to INH, RIF and SM (42/70,
60%) was the most common MDR resistance pattern. None had resistance to only INH,
RIF and ethambutol (EMB), and 6 had resistance to INH, RIF, EMB and SM.
Of the 85 XDR-TB isolates, 21 (26%) were resistant to INH, RIF, ciprofloxacin
(CPX) and kanamycin (KM) only. Six 6 (7.5%) were resistant to INH, RIF, CPX, KM
and EMB but not SM, and 24 (30%) were resistant to INH, RIF, CPX, KM and SM but
not EMB. Thirty-four (42.5%) were resistant to all six drugs tested.
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Changes in Drug Resistance Patterns
Forty-five patients had multiple sputum susceptibility patterns in the study period,
of which 30 patients had sputum isolates that fell into two or more resistance categories
(MDR-TB, XDR-TB or non-MDR-TB) (Figure 3). Of the thirty patients with sputum
isolates in more than one resistance group, 18 went from a lower to a higher resistance
group over time (e.g. non-MDR to MDR), 8 had isolates from the same week in two
different resistance groups, and 4 went from a higher to a lower resistance group (e.g.
XDR to MDR).
Among the 18 patients who had initial isolates in a lower resistance category
followed by later isolates in a higher resistance category, 7 went from non-MDR to
MDR, 8 went from non-MDR to XDR, 1 went from MDR to XDR, and 2 went from nonMDR to simultaneous MDR and XDR (Table 13). Among the seven patients having a
non-MDR isolate and a subsequent MDR isolate, the mean time between isolates was 146
days (range 69-222 days). Among those having a non-MDR isolate followed by a XDR
isolate, the mean time between isolates was 109.5 days (range 69-183 days). For the two
patients who had a non-MDR isolate followed by simultaneous isolates of MDR and
XDR-TB, the mean time was 191 days (153, 299 days).
For the single patient who had an MDR-TB isolate followed by an XDR-TB
isolate, the duration between the isolates was 260 days; the patient received
INH,RIF,EMB,SM and pyrazinamide (PZA) for three and a half weeks, followed by
second line drugs (ofloxacin, ethionamide, pyrazinamide, amikacin, ethambutol ). SLD
were given two months after the isolate for MDR-TB (INH, RIF resistance) and five
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months before the isolate for XDR-TB (INH, RIF, SM, CPX, KM resistance) was
collected.
Six of the seven patients with a fully susceptible TB in their first isolate and MDR
in their subsequent isolate had resistance to SM as well, despite never having received
SM during that period. All of the patients whose DST pattern changed from non-MDR to
XDR were hospitalized at some point during the period between collection of the isolates,
suggesting the possibility of exogenous super-infection with a more drug-resistant strain.
Two patients with MDR had increasing drug resistance: one patient had INH and
RIF resistance at baseline and INH, RIF, SM, CPX and KM (XDR-TB) after 260 days;
the other patient had INH and RIF resistance at baseline, followed by INH, RIF, SM and
KM resistance (still MDR-TB) after 33 days.
Seventy-four percent (52/70) of MDR-TB isolates had SM resistance, and 60%
(42/70) of all MDR-TB isolates had the same DST pattern of resistance to INH, RIF and
SM, despite the fact that few patients had exposure to SM. Only 5 patients with MDRTB had prior streptomycin exposure (all had resistance to SM at baseline). An additional
nine patients with MDR-TB received SM as part of initial therapy during the study
period, among whom only four had SM resistant isolates at baseline. Of these four, two
of the sputa were collected within two weeks of treatment start (2 days, 11 days), making
acquired resistant highly improbable. The other two were collected 55 and 68 days after
start of treatment. No patients receiving streptomycin were observed to have a previously
streptomycin susceptible sputum followed by a streptomycin resistant sputum.
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Table 1 Demographics and Baseline Clinical Characteristics and Symptoms by Drug Resistance Group

Non-MDR

MDR

XDR

57

52

61

MDR /
Non-MDR

XDR /
Non-MDR

XDR /
MDR

23 (40.4)

18 (34.6)

34 (55.7)

0.537

0.095

0.025

Age, years
Mean (S.D.)
Median (range)

34.5 (10.1)
32.6 (14.7-70.6)

35.4 (8.3)
33.7 (19.9-56.9)

35.1 (7.8)
34.5 (15.4-61.4)

0.420

0.350

0.947

Sputum Smear
Positive, n (%)

27 (47.4)

37 (71.2)

45 (73.8)

0.015

0.005

0.756

Extrapulmonary TB§
Present, n (%)

14 (24.6)

16 (30.8)

18 (29.5)

0.469

0.546

0.884

Hemoglobin (g/dL), n
Median (IQR)

45
9.0 (7.5-10.5)

43
9.3 (8.0-11.4)

53
9.3 (7.8-10.8)

0.237

0.435

0.602

ESR (mm/h), n
Median (IQR)

28
115.5 (74-130)

32
95.0 (53.5-126.5)

37
100.0 (55-123)

0.187

0.272

0.834

Weight (kg)
Women, n
Median (IQR)
Men, n
Median (IQR)

15
53.0 (46.0-60.0)
24
52.0 (48.0-54.5)

12
47.5 (45.0-54.8)
21
51.0 (45.0-54.0)

16
49.25 (43.6-54.0)
22
50.5 (47.0-60.0)

0.338

0.252

0.945

0.455

0.870

0.301

35 (61.4)

33 (63.5)

36 (59.0)

0.918

0.783

0.707

Yes, n (%)

46 (80.7)

39 (75.0)

49 (80.3)

0.365

0.802

0.497

Night Sweats
Yes, n (%)

18 (31.6)

16 (30.8)

23 (37.7)

0.878

0.529

0.440

25 (43.9)

19 (36.5)

27 (44.3)

0.392

0.967

0.405

Total, N

P Values

Sex
Women, n (%)

Weight Loss
Yes, n (%)
Cough

Fever
Yes (n,%)

§ All patients had pulmonary TB as well. Extrapulmonary TB patients had pulmonary
and extrapulmonary disease.
Statistically significant values are in bold.
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Table 2 HIV-related Clinical Information By Drug Resistance Group

Total, N

Non-MDR

MDR

XDR

57

52

61

MDR /
Non-MDR

XDR /
Non-MDR

XDR /
MDR

P Values
Tested For HIV
n (%)

47 (82.5)

40 (76.9)

57 (93.4)

0.472

0.065

0.012

HIV Positive
n (% of tested)

44 (93.6)

37 (92.5)

57 (100)

1.000

0.089

0.067

2 (4.5)

2 (5.4)

8 (14.0)

1.000

0.180

0.306

11 (25.0)

9 (24.3)

19 (33.3)

0.944

0.334

0.323

8
5.6 (5.0-6.1)
0

13
5.2 (4.6-6.0)
0

20
5.1 (3.2-5.7)
5 (3)

0.690

0.177

0.269

CD4 at Diagnosis*
n
median (IQR)

24
70.5 (36-131.5)

27
57 (34-104)

28
56 (19-156.5)

0.461

0.344

0.561

<50 (n,%)

9 (37.5)

12 (44.4)

12 (42.9)

0.777

0.781

1.000

50-200 (n,%)

10 (41.7)

10 (37.0)

12 (42.9)

0.780

1.000

0.785

>200 (n,%)

5 (20.8)

5 (18.5)

4 (14.3)

1.000

0.716

0.729

On ART
Before TB Diagnosis
n (% of HIV+)
Ever
n (% of HIV+)
VL at Diagnosis*
n
Log Median (IQR)
n on ART (VL<25)

VL = Viral Load; OR = Odds Ratio; IQR = Interquartile Range; CI= Confidence Interval; ART = Antiretroviral Therapy
*Values were included if performed within 120 days of start of TB treatment
CD4 counts are cells / mm3; Viral Load is expressed in copies per mL
Statistically significant values are in bold.
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Table 3 Previous TB Treatment and Previous Hospitalizations by Drug Resistance Group

MDR /
Non-MDR

XDR /
Non-MDR

XDR /
MDR

Non-MDR

MDR

XDR

57

52

61

Previous TB Treatment
Any, n (%)

15 (26.3)

31 (59.6)

26 (42.6)

4.13
(1.84-9.28)

2.08
(0.96-4.53)

0.50
(0.24-1.07)

Past Year, n (%)

2 (3.5)

17 (32.7)

17 (27.9)

13.36
(2.91-61.39)

10.63
(2.33-48.48)

0.80
(0.36-1.78)

Previous Hospitalization
Any, n (%)

12 (21.1)

22 (42.3)

25 (41.0)

2.75
(1.19-6.38)

2.6
(1.15-5.89)

0.95
(0.45-2.01)

8 (14.0)

19 (36.5)

23 (37.7)

3.53
(1.38-9.00)

3.71
(1.49-9.20)

1.02
(0.47-2.20)

Total, N

Past 2 Years, n (%)

Previous hospitalizations were not limited to admissions for TB.
Statistically significant values are in bold.
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OR
(95% CI)

Table 4 Risk Factors for MDR-TB in Logistic Regression Model (comparison with non-MDR-TB)

Unadjusted OR

95% CI

Adjusted OR

95%CI

1.28
13.36
3.53
2.74

0.59-2.78
2.91-61.39
1.38-9.00
1.24-6.06

1.24
8.33
1.69
1.59

0.52-3.00
1.64-42.33
0.56-5.09
0.66-3.81

Male Sex
TB Treatment in Last Year
Hospitalized in Last 2 Years
Sputum Smear Positive
Statistically significant values are in bold.

Table 5 Risk Factors for XDR-TB in Logistic Regression Model (comparison with non-MDR-TB)

Unadjusted OR

95% CI

Adjusted OR

95%CI

0.54
10.63
3.71
3.13

0.26-1.12
2.33-48.48
1.49-9.20
1.44-6.76

0.45
7.19
1.81
2.79

0.20-1.03
1.35-38.17
0.62-5.25
1.20-6.47

Male Sex
TB Treatment in Last Year
Hospitalized in Last 2 Years
Sputum Smear Positive
Statistically significant values are in bold.

Table 6 Risk Factors for XDR-TB in Logistic Regression Model (comparison with MDR-TB)

Unadjusted OR

95% CI

Adjusted OR

95%CI

0.42
0.8
1.02
1.14

0.20-0.90
0.36-1.78
0.47-2.20
0.50-2.61

0.41
0.79
1.19
1.39

0.19-0.89
0.31-2.00
0.49-2.86
0.56-3.42

Male Sex
TB Treatment in Last Year
Hospitalized in Last 2 Years
Sputum Smear Positive
Statistically significant values are in bold.
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Table 7 Demographics and Baseline Clinical Characteristics by Outcome

Died

Alive/Unknown

111

59

Sex
Female, n (%)

50 (45.0)

25 (42.4)

0.738

Age
Median (IQR)

33.9 (29.4-39.9)

33.4 (27.9-39.1)

0.480

Extrapulmonary TB
Present, n (%)

36 (32.4)

12 (20.3)

0.095

Sputum Smear
Positive, n (%)

79 (71.2)

30 (50.8)

0.007

95
9.1 (7.8-10.6)

46
9.3 (7.5-11.2)

0.958

ESR (mm/h), n
Median (IQR)

63
99 (57-123)

34
114 (60-130)

0.354

Weight (kg)
Women, n
Median (IQR)
Men, n
Median (IQR)

26
48.3 (45-53.5)
44
51.5 (46-54.5)

17
53 (46-60)
23
52 (45-56)

Total, N

Hemoglobin (g/dL), n
Median (IQR)

Statistically significant values are in bold.
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P Values

0.111
0.400

Table 8 HIV-related Clinical Information by Outcome

P
Values

Died

Alive/Unknown

111

59

Tested for HIV
n (%)

95 (85.6)

49 (83.1)

0.662

HIV Positive
n (% of tested)

92 (96.8)

46 (93.9)

0.409

2.00 (0.39-10.30)

21 (22.8)

18 (39.1)

0.049

0.44 (0.21-0.95)

9 (9.8)

3 (6.5)

0.522

1.50 (0.39-5.83)

54 (58.7)
53.5 (25-95)

25 (54.3)
104 (41-225)

0.552

26 (48.1)
23 (42.6)
5 (9.3)

7 (28.0)
9 (36.0)
9 (36.0)

0.004
0.021
0.004

29
5.23 (4.63-5.89)
4 (2)

12
5.28 (2.45-5.82)
1 (1)

0.82

Total, N

On ART
Total
n (% of HIV+)
Before TB Diagnosis
n (% of HIV+)
CD4 at TB Diagnosis*
n (% of HIV+)
Median (IQR)
<50
50-200
>200
VL at TB Diagnosis*
N
Log Median
n on ART (VL < 25)

VL = Viral Load; OR= Odds Ratio; CI= Confidence Interval; IQR = Interquartile Range
*Values were included if performed within 120 days of start of TB treatment
CD4 counts are cells / mm3; Viral Load is expressed in copies per mL
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OR (95% CI)

6.69 (1.69-26.45)
4.60 (1.21-17.52)
Referent

Table 9 Previous TB Treatment and Previous Hospitalizations by Outcome

Died

Alive/Unknown

P Values

OR (95% CI)

111

59

Any, n (%)

49 (44.1)

23 (39.0)

0.517

1.24 (0.652.35)

Past Year, n (%)

28 (25.2)

8 (13.6)

0.076

2.15 (0.915.08)

Any, n (%)

44 (39.6)

15 (25.4)

0.064

1.93(0.963.87)

Past Years, n (%)

31 (27.9)

9 (15.3)

0.064

2.15(0.954.90)

Total, N
Previous TB Treatment

Previous Hospitalization*

*Previous hospitalizations were not limited to admissions for TB.
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Table 10

Risk Factors for Mortality from Start of TB Treatment
in Cox Proportional Hazards Model

Male Sex
TB Treatment in Last Year
Hospitalized in Last Year
Sputum Smear Positive
XDR-TB
MDR-TB
CD4 less than 200/mm3

HR

95% CI

P value

0.90
1.60
1.57
2.09
2.50
2.00
3.23

0.45-1.35
1.08-2.12
1.08-2.06
1.60-2.58
1.92-3.08
1.38-2.62
2.13-4.33

0.658
0.077
0.073
0.003
0.002
0.028
0.037

Statistically significant values are in bold.

Table 11

Risk Factors for Mortality from Time of Diagnostic Sputum
Collection in Cox Proportional Hazards Model

Male Sex
Treatment in Last Year
Hospitalized in Last Year
Sputum Smear Positive
XDR-TB
MDR-TB
CD4 less than 200/mm3

HR

95% CI

P value

1.09
1.29
1.24
2.36
4.31
3.09
4.69

0.64-1.54
0.78-1.80
0.76-1.72
1.88-2.84
3.71-4.91
2.47-3.71
3.59-5.79

0.718
0.321
0.378
<0.001
<0.0001
<0.001
0.006

Statistically significant values are in bold.
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Table 12 Drug Resistance Patterns Found and Their Frequencies

Resistance Class

Drug Resistance Pattern

Drug Susceptible

--

66

Monoresistant

INH
RIF

5
2

Polyresistant

INH, SM

1

Multidrug-Resistant

INH, RIF
INH, RIF, SM
INH, RIF, KM
INH, RIF, SM, KM
INH, RIF, EMB, SM
INH, RIF, EMB, SM, CPX

17
42
1
2
6
2

Extensively Drug-Resistant

INH, RIF, CPX,
INH, RIF, CPX,
INH, RIF, CPX,
INH, RIF, CPX,

21
6
24
34

KM
KM, EMB
KM, SM
KM, EMB, SM

Total

Frequency, n*

229

INH = Isoniazid; RIF = Rifampicin; EMB = Ethambutol;
SM = Streptomycin; CPX = Ciprofloxacin; KM = Kanamycin
* Multiple isolates from the same patient with the same resistance pattern were
only counted once
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Table 13

Drug Resistance Patterns and Timing of Isolate Collection for Patients with Multiple
Resistance Patterns Conferring Changes in Resistance Category

Days
Pt

Outcome

Days

Days

Days

Isolate 1

Iso 1 to

Isolate 2

Iso 2 to

Isolate 3

Iso 3 to

Isolate 4

Iso 4 to

Isolate 5

Resist.

Iso 2

Resist.

Iso 3

Resist.

Iso 4

Resist.

Iso 5

Resist.

non-MDR to MDR Only
1

death

none

137

HRS

--

--

--

--

--

--

2

death

none

175

HRES

--

--

--

--

--

--

3

death

none

78

HRS

--

--

--

--

--

--

4

death

none

69

HRS

--

--

--

--

--

--

5

alive

none

187

HR

--

--

--

--

--

--

6

death

none

6

none

222

HRS

--

--

--

--

7

death

none

154

HRES

0

HRS

--

--

--

--

--

non-MDR to XDR
8

death

none

94

HRCK

--

--

--

--

--

9

death

none

101

HRSCK

1

HRSCK

0

HRESCK

--

--

10

death

none

69

HRESCK

--

--

11

unknown

none

48

none

132

HRESCK

72

HRESCK

0

HRSCK

12

Alive

none

80

HRCK

--

--

--

--

--

--

13

Death

none

183

HRESCK

--

--

--

--

--

--

14

Death

none

32

none

68

HRCK

--

--

--

--

15

Death

none

6

none

63

HRSCK

--

--

--

--

non-MDR to MDR/XDR
16

Death

none

153

HRS

0

HRSCK

--

--

--

--

17

Death

none

229

HRK

0

HRESCK

--

--

--

--

alive

HR

260

HRSCK

--

--

--

--

--

--

MDR to XDR
18

Pt = Patient; Iso = Isolate; Resist. = Resistance
Days Iso 1 to Iso 2 = Days between collection of isolate 1 and isolate 2
H = Isoniazid; R = Rifampicin; E = Ethambutol; S = Streptomycin; C = Ciprofloxacin; K = Kanamycin
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Figure 1 Survival by Drug Resistant Group from TB Treatment Start*

Legend
MDR
non-MDR
XDR
MDR-censored
non-MDR-censored
XDR-censored

Proportion surviving

1.0

0.8

0.6

0.4

0.2

0.0
0

50

100

150

200

250

300

350

Days of survival from TB treatment start
*Kaplan-Meier survival analysis. Patients were censored (no longer represented) in the survival curve at
the last point in time in which they were seen by a health provider.
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Figure 2 Survival by Drug Resistance Group from Sputum Collection Time*

tbcat2
MDR
non-MDR
XDR
MDR-censored
non-MDR-censored
XDR-censored

1.0

Proportion Surviving

0.8

0.6

0.4

0.2

0.0
0

200

400

Days of survival from sputum collection
*Kaplan-Meier survival analysis. Patients were censored (no longer represented) in the survival curve at
the last point in time in which they were seen by a health provider. Sputum collection refers to the
collection of the sputum for culture and DST that was used for assignment to a drug resistance group (nonMDR, MDR or XDR).
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Figure 3 Patients with Multiple Resistance Patterns During Study Period
All Patients in Study (N=170)

Patients with Only One
Resistance Pattern
During Study Period (n=125)
Patients with Multiple Resistance
Patterns During Study Period
(n=45)
Patients with Multiple Isolates from
1
Same Resistance Category (n=15)
Patients with Isolates from Two
1
or More Resistance Categories
(n=30)

Patients with Increasing
Resistance (n=18)
Non-MDR to MDR (7)
Non-MDR to XDR (8)
Non-MDR to MDR and XDR (2)
MDR to XDR (1)

Patients with Simultaneous
Isolates in Two
1
Resistance Categories
(n=8)

1

Patients with Decreasing
Resistance (n=4)
XDR to MDR (1)
MDR to Non-MDR (3)

Resistance categories were MDR-TB, XDR-TB and non-MDR-TB as previously
defined.
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DISCUSSION
In this study in rural KwaZulu Natal, South Africa, we performed detailed
analysis of cases of drug sensitive and drug resistant TB. In our previous report of XDRTB in this setting (41), we found near universal mortality, occurring in a median of 16
days after sputum was obtained for TB culture. Many patients received the diagnosis
post-mortem and most had the opportunity to transmit resistant organisms to others
before diagnosis was made. These observations illustrated the critical need for early
identification of patients with drug resistant TB and prompted this study. Due in part to
the paucity of laboratory capacity for DST in Sub-Saharan Africa, there have been few
reports of clinical predictors of MDR-TB in the high TB prevalence and high HIV
prevalence settings of this region. We sought to further characterize the clinical
manifestations and outcomes of XDR-TB and MDR-TB with comparison to non-MDRTB in order to identify characteristics that might result in earlier diagnosis. Our results
have provided some information which might be of clinical utility in this regard. We
confirmed the high mortality associated with XDR-TB in this setting and found high rates
of mortality among patients with MDR-TB as well. More than ninety percent of tested
patients in all groups were HIV-infected, and a positive sputum smear was independently
associated with both drug resistance and mortality in this population. Previous TB
treatment in the last year and hospitalization in the past two years predicted drug resistant
TB. MDR-TB appeared to be more often due primary drug resistance, including superinfection of fully susceptible TB, than acquisition of drug resistance. Amplification of
resistance among patients with MDR-TB and XDR-TB was not widely observed. This
study and the findings noted above represent the first description of clinical
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characteristics of patients with extensively drug-resistant tuberculosis and the first
comparative examination of risk factors and outcomes for non-MDR, MDR and XDRTB.

Clinical Predictors of MDR-TB and XDR-TB
Clinical predictors of MDR-TB and XDR-TB did not differ significantly, and
apart from the interesting association with positive sputum smear, were consistent with
previously described risk factors for drug resistant tuberculosis. The strongest clinical
predictors of drug resistant tuberculosis (both MDR-TB only and XDR-TB) were TB
treatment in the previous year, hospitalization in the previous two years and positive
sputum smear. In numerous studies of risk factors for drug-resistant TB, previous TB
treatment—particularly in the context of treatment default, treatment failure, or relapsed
TB—has been consistently found to predict MDR-TB (67-74). Studies comparing drug
susceptible TB and MDR-TB have found previous TB treatment to be associated with
odds ratios ranging from 2 to more than 10. Data on outcomes of previous TB treatment
were not available for this study. However, studies have found that even among MDRTB patients found to be cured under short-course chemotherapy, 30% subsequently
relapsed (113), suggesting that previous treatment cure may not reliably exclude drugresistant TB.
While there was a strong association between previous TB treatment and drugresistant TB, it is of great importance to note our finding that 40% of MDR-TB patients
and nearly 60% of XDR-TB patients had no previous TB treatment. Moreover, the
majority of MDR-TB patients had streptomycin resistance without previous exposure to
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streptomycin. Together, these findings suggest that much—if not the majority—of
MDR-TB in this setting is due to transmitted (or primary) drug resistance.
Previous treatment for MDR-TB may not only represent acquisition of drug
resistant TB (by incomplete or inappropriate treatment), the sense in which previous
treatment is usually assumed to be a risk factor in many of the aforementioned studies.
Rather, this association between previous treatment and MDR-TB may, in part, be
understood similarly to the association between previous treatment and XDR-TB (the
proportion with previous treatment in the MDR-TB and XDR-TB groups were not
statistically different), which can be explained as follows. Since no XDR-TB patients
had prior exposure to second-line drugs (SLD), XDR-TB was likely all primary
resistance. The association with previous treatment was likely due to two causes: many
XDR-TB patients were treated with first-line drugs at first TB diagnosis because DST
wasn’t performed; and previous TB diagnosis resulted in hospitalization, which was a
risk factor for super-infection with XDR-TB. While some MDR-TB may have been
attributable to acquired drug resistance from previous failed treatment, much of the
association with previous treatment may be explained by this other mechanism.
Previous hospitalization and hospitalization in the past two years were significant
risk factors for MDR-TB and XDR-TB on bivariate analysis but were not found to be
significant independent risk factors on multivariate analysis. The association between
previous hospitalization and development of drug resistant tuberculosis may be expected
due to the favorable conditions for nosocomial spread of drug resistant TB at COSH;
however, the independence of previous hospitalization from previous TB treatment as
risk factors might not have emerged due to the fact that the greatest risk for nosocomial
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transmission is on the TB wards, and for hospitalized patients to be at great risk of
acquiring MDR or XDR-TB, they would have to be undergoing treatment for TB (on
these and not other wards). Notably, among the ten patients with pan susceptible isolates
who later had an XDR-TB isolate (Table 13), all were hospitalized between the collection
of the two isolates.
Overall, 88% of patients were hospitalized at the time of admission, and median
hospitalization for non-MDR patients was 13 days. Even during this relatively short stay,
these patients might have encountered drug resistant TB. At present, there is inadequate
hospital space to provide for isolation of patients with unknown TB resistance patterns,
so patients with drug resistant TB (whose status is usually unknown initially) are first
admitted to the general TB ward with all other TB patients. Reserving hospital admission
to TB wards for patients who are critically ill and shortening hospitalization times may
reduce the risk of nosocomial transmission of drug resistant TB.
Female sex was a statistically significant independent risk factor for XDR-TB
compared with MDR-TB. There is a lack of additional social analysis necessary to fully
explore this association; simple potential explanations that may have contributed to this
finding include higher rates of XDR-TB transmission on the Female TB wards,
documented higher rates of HIV among women in this region, and the high rates of
seasonal labor migration among men, which could either cause them to be
disproportionately represented in non-MDR-TB patients while providing a protective
factor of being away from a community or hospital with high levels of XDR-TB
transmission.
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The proportion of patients with a positive sputum smear was higher among XDRTB and MDR-TB patients than among non-MDR-TB patients. This differential rate may
be in part due to period in time between start of TB treatment and collection of sputum
for smear and culture (median 7.5 days, third quartile 68 days); patients with non-MDRTB would be likely to have a reduction in their bacillary load through standard first-line
therapy during this time, while patients with MDR-TB and XDR-TB would be less likely
to achieve this suppression. Sputum smear detection typically requires 5,000-10,000
organisms per milliliter, while culture can detect as low as 10-100 viable organisms per
milliliter (114). Therefore culture could still be positive in the non-MDR-TB patients
while smear may have already turned negative. The proportion of patients with positive
smear in the MDR and XDR-TB groups in this study were higher than values reported in
the literature for HIV patients, and 90% of patients in both groups were HIV positive.
Elliott et al. found 43% and 24% of HIV-infected and uninfected patients with culture
proven TB to be sputum smear negative (98). Other studies have found higher
proportions of sputum negative TB among HIV-infected patients compared with HIV
uninfected patients, but not necessarily in the context of culture positive TB (for example,
due to extrapulmonary TB) (115). Finally, this finding may represent more severe
disease (e.g. cavitary disease) among MDR-TB and XDR-TB patients, many of whom
had prior TB treatments and may have been identified later in their course of disease.
The prevalence of HIV did not differ greatly between the three drug resistance
groups and for all groups was slightly higher than the reported prevalence of HIV among
TB patients in the province; not all patients were tested for HIV, however, and
geographic variability of HIV prevalence within the province may partially explain these
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findings. There were no HIV negative XDR-TB patients in the study. While the
literature has failed to confirm HIV as an independent risk factor for MDR-TB, higher
rates of HIV among XDR-TB patients would be expected if we assume all of this to be
recent, primary transmission of drug resistant TB. Because HIV infected individuals are
more likely to manifest TB disease within the first year after infection, they would be
over-represented in the early phases of this emerging drug resistant-TB epidemic
compared to non-HIV-infected individuals, who have a lower chance of progressing to
primary disease following initial infection. Moreover, HIV infected patients are
overrepresented on hospital wards and are more likely to be admitted with TB disease
than HIV-uninfected patients; this puts them at increased risk for nosocomial acquisition
of XDR-TB.

Predictors of Mortality
Mortality was high for all three drug resistance groups. While mortality was
greater and median survival shorter for XDR-TB patients than MDR-TB only patients,
the difference was not significant, and the two groups had remarkably similar survival
trajectories on Kaplan-Meier analysis (see Figure 1). This may be in part due to the fact
that survival prior to receipt of SLD may be very similar for MDR compared to XDR-TB
patients. For XDR-TB patients with susceptibility to ethambutol, first line therapy would
contain an equal number of active agents against this form of XDR-TB as would be
available to those with MDR-TB (ethambutol and possibly pyrazinamide).
In our previous report, medial survival for XDR-TB patients was 16 days from
time of sputum collection (41). In this study, median survival from sputum collection
was 14 days for XDR-TB, 22 days for MDR-TB and 190 days for non-MDR-TB.
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Therefore, for MDR-TB and XDR-TB patients, median survival is still shorter than the
period of time required for DST results to be available; that is, most patients died before
their diagnosis was made. Median survival from time of TB treatment start was much
longer for MDR-TB and XDR-TB patients; there are two explanations for this. One is
that, despite the hospital’s policy of collecting sputum for culture and DST on all patients
at time of diagnosis, there was a lag time between TB diagnosis and sputum collection.
The median time between treatment start and diagnostic sputum collection was 14 days
and 34 days for MDR-TB and XDR-TB patients, respectively. The second explanation is
that some patients with MDR-TB and XDR-TB had drug susceptible TB at the start of
treatment and acquired MDR-TB or XDR-TB during their initial hospitalization (we
found evidence of this in the limited number of patients with multiple sputum isolates).
The survival from sputum diagnosis in these patients would more accurately reflect the
course of disease for MDR and XDR-TB.
Significant independent predictors of mortality included MDR-TB only group,
XDR-TB group, CD4 cell count less than 200 cells/mm3 and positive sputum smear.
Neither previous TB treatment in the past year nor previous hospitalization in the past
year were statistically significant predictors of mortality on bivariate or multivariate
analysis, though both were higher among those who died, with the effect just above the
level of statistical significance. The hazard ratio of mortality from sputum collection for
patients with CD4 cell count less than 200 cells/mm3 was 4.67, highlighting the
importance of treating HIV disease as a strategy for blunting the impact of tuberculosis
and drug-resistant tuberculosis. Studies have shown that antiretroviral therapy,
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particularly if initiated early, can reduce mortality from TB, as well as TB incidence
(116, 117).
The fact that positive sputum smear was found to be a significant risk factor for
mortality on bivariate analysis was not unexpected given the finding of higher rates of
positive sputum smear among MDR and XDR patients; however, it was surprising to see
it emerge as a risk factor in the multivariate model. Smear negative tuberculosis has been
associated with higher rates of mortality, particularly among HIV-infected individuals
and in the context of severe immune compromise (5, 118). This finding may again
reflect severity of disease, whereby smear positive patients were more likely to have been
identified later in their course of illness; moreover, given that most sputa for smear were
collected after initiation of therapy, a negative sputum smear may have reflected early
smear conversion in some cases. Chest radiograph review was not performed, but may
help in further clarifying this association.
Patients in the surviving group were significantly more likely to receive ART;
however, it is difficult to discern whether this represents an actual survival benefit
accorded by the use of antiretrovirals or the fact that those surviving had a longer period
in which to access antiretrovirals. In patients with a new diagnosis of TB and a CD4
count over 50 cells/mm3, ART is often deferred for two months, until the end of intensive
phase of tuberculosis therapy. Those surviving for more than two months would thus
have a greater chance of receiving ART.
The mortality rate among MDR-TB only patients (73.1%) was high in comparison
to values in the literature (107). Only 19% of MDR-TB patients received second-line
drugs, due in part to early mortality and loss to follow-up of patients. All patients are
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provided SLD through the public hospital system; however, given that the median time to
sputum collection was 2 weeks, DST results take three to six weeks, and the median
survival among all MDR patients was around three months, many patients died before
accessing SLD. Even among patients receiving SLD for MDR-TB, a case series from
South Africa found treatment success rates of 47% for HIV negative patients and 38% for
HIV positive patients, both well under the norm for WHO DOTS Plus programs (107).
The mortality rate for non-MDR-TB patients (36.8%) was consistent with the
values in the literature for mortality (around 40%) among TB patients with untreated HIV
in the region (5). However, the follow-up was poor for non-MDR patients in particular,
with subsequent hospitalization or death being the most common reasons for having
follow-up data on these patients, thereby biasing the Kaplan-Meier curves towards
mortality by having little follow-up among surviving patients. The high mortality and
similarity to that of untreated HIV disease may be related to the fact that only 20%
received ART, as many patients were lost to follow-up. Furthermore, two patients from
the non-MDR-TB group went on to develop MDR-TB, and both died; four patients from
this group went on to develop XDR-TB, with three dying. Therefore, 5 of the 21 deaths
in non-MDR-TB patients, or almost one quarter, involved subsequent development of
drug resistant tuberculosis. As later sputum DST were not available for most patients,
additional initially drug sensitive patients could well have acquired drug resistant TB.
Therefore this figure is a lower limit for the contribution of drug resistant TB to mortality
in patients presenting with non-MDR-TB.

Observed Drug Resistance Patterns and Changes in Resistance
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Eighty-nine percent of non-MDR isolates were fully susceptible; only seven (9%)
isolates were mono-resistant and just one (1%) had poly-resistance. No ethambutol
(EMB), streptomycin (SM), kanamycin (KM) or ciprofloxacin (CPX) mono-resistant
strains were found. Several small studies have provided indirect and limited evidence
that empiric use of quinolones, for pathogens and diseases unrelated to TB or to exclude a
diagnosis of pneumonia in cases where a TB diagnosis is possible, may lead to acquired
resistance of tuberculosis to quinolones (18-20). The health governance in the
Philippines, for example, has taken steps to limit the empiric use of quinolones citing this
concern. However, in this study, there were no instances of monoresistance to
ciprofloxacin. Except in two isolates, CPX resistance was only seen in the context of
KM resistance (likewise, except in 3 isolates, KM resistance was only seen along with
CPX resistance), suggesting that primary transmission of a strain with resistance to both
drugs, rather than empiric use of either drug, is responsible for resistance seen in this
setting.
The predominance of SM-resistant strains among MDR-TB isolates, particularly
in light of the fact that few patients received SM, suggests that primary (transmitted) drug
resistance accounted for much—perhaps the majority—of MDR-TB in this population.
This was evidenced among the small number of patients with multiple sputum isolates:
seven patients with fully susceptible tuberculosis had MDR-TB with streptomycin
resistance at a later date, and none had received SM during this period; this is strongly
suggestive of primary, transmitted resistance. In contrast, only one patient acquired INH
and RIF resistance without acquiring SM resistance. Moreover, one permutation—
resistance to INH, RIF, and SM—accounted for 60% of all (non-XDR) MDR-TB,
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suggesting that a single drug resistant strain may be spreading quickly in this population,
perhaps the result of a relative fitness. Genetic analysis (e.g. spoligotyping, restriction
fragment length polymorphism) is planned and may further clarify the genetic similarity
of these isolates.
Only one patient had an initial isolate of MDR-TB and subsequent isolate of
XDR-TB; this patient had exposure to second line drugs for five months between the
collection of the two isolates, making it possible that this change represented
amplification of resistance.
Among XDR-TB strains, there was heterogeneity of resistance patterns found.
The most frequently observed strain (resistance to all six drugs) accounted for less than
half (42.5%) of all isolates. It is therefore likely that multiple XDR strains with varying
resistance patterns are circulating in this setting; while amplification of resistance among
XDR patients was not observed in this study, it is likely to happen when XDR patients
with EMB or SM susceptibility are exposed to first line or re-treatment therapy
(including SM) for long durations. A subset of patients with resistance to all six drugs
had DST performed for pyrazinamide, and PZA-resistance was observed (119). First line
therapy or re-treatment therapy used in patients with XDR-TB may thus contain at most
only one or two active drugs, which may result in the development of resistance to these
agents. Early identification of XDR-TB patients is thus particularly crucial for the
preservation of these agents for use in combination with SLD.

Study Limitations
There were several important limitations to this study. Many of these stemmed
from the fact that this was a retrospective study in a resource-limited setting based on
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chart review; as such, a limited number of charts were available and important data was
missing from many charts and other data sources.
Analysis of clinical predictors of drug resistance was limited by missing data for
variables identified as potential predictors, including previous TB treatment outcomes,
weight changes over the initial months of treatment, two month sputum smear, baseline
chest radiograph and two month chest radiograph. Because of the lack of differences in
many baseline clinical characteristics, close examination of these clinical predictors in the
initial period of TB treatment may provide more useful tools for distinguishing drug
susceptible from drug resistant TB. Such data would be more systematically obtained
through prospective investigation.
The second major limitation of the study was the short follow-up period and lack
of TB outcomes data for non-MDR-TB patients, both of which may have biased the
mortality analyses (underestimating mortality in this group by failing to include patients
who died at home or elsewhere); this data is currently being collected for patients from
this group. However, given that the mortality among this group was very similar to the
literature value for TB among patients with untreated HIV disease, it is unlikely that
mortality among these patients was significantly underestimated.
A third limitation is that aminoglycoside and fluoroquinolone use for reasons
other than tuberculosis therapy were not recorded in the database. It is possible that
exposure to these drugs for other purposes impacted resistance; however, given the
absence of observed monoresistance for SM, KM or CPX, it is unlikely that short-term
exposure to fluoroquinolones or aminoglycosides played a large role in TB drug
resistance in this setting.
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Drug susceptibility testing by the proportions method is subject to false positives
and false negatives; most laboratories report an error of around 1-3% due to variations in
performance and interpretation of the test, making clinical judgment an important factor
in determining management of drug resistant TB patients. The laboratory reporting
results for this study underwent weekly external quality assessment as described in the
Methods; the risk of cross contamination affecting results was therefore limited.
While assumptions can be made about the role of transmitted drug resistance
among MDR-TB and XDR-TB patients in this study given the findings of resistance to
drugs in the absence of their exposure, genotype data will further clarify the
epidemiology and solidify these findings. Genotyping is underway and analysis of the
results with reference to this clinical data is planned.
The final important limitation of these related to the assignment of patients into
TB categories. Four patients in the MDR-TB only group and five patients in the XDR
group had non-MDR-TB isolates only at the time of TB diagnosis. For clinical predictors
and calculations of survival from the time of TB diagnosis, these patients may have been
more similar to non-MDR patients than to other MDR only or XDR patients. We felt it
was important not to exclude these patients or reassign them to the non-MDR-TB group
as they were not selected randomly like the non-MDR-TB group and therefore would
have biased outcomes of that group. Additionally, excluding them from the MDR-TB
and XDR-TB group would remove all patients with prior fully susceptible TB, biasing
those groups away from transmitted resistance. Moreover, it is possible that these
patients had mixed infection at the time of diagnosis and under first-line therapy, the drug
susceptible strain was suppressed; mixed infections at the time of diagnosis were very
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common—ten patients had isolates at the time of diagnosis belonging to two drug
resistance groups (more may have been mixed infections in which both strains were not
isolated).
Despite these limitations, this represents the largest study of clinical
characteristics of drug-resistant tuberculosis in a HIV prevalence setting, and many
important observations emerged. Larger, prospective studies are needed to confirm and
clarify these findings.

Conclusion
The results of this study indicate that MDR-TB and XDR-TB carry a high
mortality in this high HIV-prevalence setting. Because patients did not have prior
exposure to SLD and the majority of XDR-TB patients had no previous TB treatment,
this study adds evidence to our previous report suggesting that XDR-TB in this setting
was predominantly, if not entirely, the result of primary, transmitted drug resistance.
Moreover, these results suggest that primary MDR-TB is responsible for much—if not
the majority—of MDR-TB in this setting, as well. The median survival for both MDR
and XDR-TB patients in this study was approximately three months from TB diagnosis
and two to three weeks from sputum collection. This short period leaves only a small
window for identification of drug resistance and intervention. Further, the majority of
patients are admitted to large, common TB wards before drug resistance diagnosis is
made. Thus large numbers of patients are exposed to drug resistant organisms while
hospitalized. Together, these highlight the critical need for improved infection control
and clinical and laboratory tools for the early recognition of drug resistant TB. These
include rapid culture and resistance testing techniques and clinical algorithms. Although
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much attention is now focused on the development of sophisticated molecular diagnostics
for drug resistance, these are expensive and will likely remain unavailable for most
patients in Sub-Saharan Africa. Moreover, currently few sites in Africa can perform DST
in the conventional manner, with attendant delay in results. Therefore, further research is
needed to elucidate clinical predictors of drug resistant TB, which may help with
targeting DST and could result in early identification and treatment in drug resistant
patients. We hope that the current work is a step in the development of such procedures.

69

REFERENCES
1.
2.
3.
4.

5.

6.

7.

8.

9.
10.

11.

12.

13.
14.

WHO. World Health Report 2004: Changing History. Geneva: World Health
Organization, 2004.
WHO. Global tuberculosis control: surveillance, planning, financing. WHO
Report 2006. Geneva, World Health Organization (WHO/HTM/TB/2006.362).
Murray, J.F. 2001. A thousand years of pulmonary medicine: good news and bad.
European Respiratory Journal 17:558-565.
Lawn, S.D., Bekker, L.G., Middelkoop, K., Myer, L., and Wood, R. 2006. Impact
of HIV infection on the epidemiology of tuberculosis in a peri-urban community
in South Africa: the need for age-specific interventions. Clin Infect Dis 42:10401047.
Corbett, E.L., Watt, C.J., Walker, N., Maher, D., Williams, B.G., Raviglione,
M.C., and Dye, C. 2003. The growing burden of tuberculosis: global trends and
interactions with the HIV epidemic. Archives of Internal Medicine 163:10091021.
Corbett, E.L., Marston, B., Churchyard, G.J., and De Cock, K.M. 2006.
Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the
era of antiretroviral treatment. Lancet 367:926-937.
Fox, W., Ellard, G.A., and Mitchison, D.A. 1999. Studies on the treatment of
tuberculosis undertaken by the British Medical Research Council tuberculosis
units, 1946-1986, with relevant subsequent publications. International Journal of
Tuberculosis & Lung Disease 3:S231-279.
Wolinksy, E., Reginster, A., and Steenken, W. 1948. Drug resistant tubercle
bacilli in patients under treatment with streptomycin. American Review of
Tuberculosis 58:335.
1949. Medical Research Council: Treatment of pulmonary tuberculosis with
streptomycin and para-aminosalicylic acid. British Medical Journal 2:1521-1525.
1955. Medical Research Council: Various combinations of isoniazid with
streptomycin or with PAS in the treatment of pulmonary tuberculosis. British
Medical Journal 7:435-445.
Rich, M. 2006. Diagnosis and Treatment of Multidrug-Resistant Tuberculosis. In
Tuberculosis: A Comprehensive, International Approach. M.C. Raviglione,
editor. New York: Informa Healthcare USA, Inc. 417-458.
Colangeli, R., Helb, D., Sridharan, S., Sun, J., Varma-Basil, M., Hazbon, M.H.,
Harbacheuski, R., Megjugorac, N.J., Jacobs, W.R., Jr., Holzenburg, A., et al.
2005. The Mycobacterium tuberculosis iniA gene is essential for activity of an
efflux pump that confers drug tolerance to both isoniazid and ethambutol.
Molecular Microbiology 55:1829-1840.
Brennan, P.J., and Nikaido, H. 1995. The envelope of mycobacteria. Annual
Review of Biochemistry 64:29-63.
Warner, D.F., and Mizrahi, V. 2006. Tuberculosis chemotherapy: the influence of
bacillary stress and damage response pathways on drug efficacy. Clinical
Microbiology Reviews 19:558-570.

70

15.

16.

17.
18.
19.

20.

21.

22.

23.
24.
25.

26.

27.

28.

1952. Medical Research Council. Treatment of pulmonary tuberculosis with
isoniazid; an interim report to the Medical Research Council by their Tuberculosis
Chemotherapy Trials Committee. Br Med J 2:735-746.
Farmer, P., Robin, S., Ramilus, S.L., and Kim, J.Y. 1991. Tuberculosis, poverty,
and "compliance": lessons from rural Haiti. Seminars in Respiratory Infections
6:254-260.
Farmer, P. 1997. Social scientists and the new tuberculosis.[see comment]. Social
Science & Medicine 44:347-358.
Ginsburg, A.S., Grosset, J.H., and Bishai, W.R. 2003. Fluoroquinolones,
tuberculosis, and resistance. The Lancet Infectious Diseases 3:432-442.
Sterling, T.R. 2004. The WHO/IUATLD diagnostic algorithm for tuberculosis
and empiric fluoroquinolone use: potential pitfalls. International Journal of
Tuberculosis & Lung Disease 8:1396-1400.
Grimaldo, E.R., Tupasi, T.E., Rivera, A.B., Quelapio, M.I., Cardano, R.C.,
Derilo, J.O., and Belen, V.A. 2001. Increased resistance to ciprofloxacin and
ofloxacin in multidrug-resistant mycobacterium tuberculosis isolates from
patients seen at a tertiary hospital in the Philippines.[see comment]. International
Journal of Tuberculosis & Lung Disease 5:546-550.
Bishai, W.R., Graham, N.M., Harrington, S., Page, C., Moore-Rice, K., Hooper,
N., and Chaisson, R.E. 1996. Brief report: rifampin-resistant tuberculosis in a
patient receiving rifabutin prophylaxis. New England Journal of Medicine
334:1573-1576.
Ridzon, R., Whitney, C.G., McKenna, M.T., Taylor, J.P., Ashkar, S.H., Nitta,
A.T., Harvey, S.M., Valway, S., Woodley, C., Cooksey, R., et al. 1998. Risk
factors for rifampin mono-resistant tuberculosis. American Journal of Respiratory
& Critical Care Medicine 157:1881-1884.
2003. Partners in Health. The PIH Guide to Medical Management of MultidrugResistant Tuberculosis. Boston: Partners in Health.
2006. World Health Organization. Guidelines for the Programmatic Management
of Drug-Resistant Tuberculosis. Geneva: WHO.
Meier, A., Sander, P., Schaper, K.J., Scholz, M., and Bottger, E.C. 1996.
Correlation of molecular resistance mechanisms and phenotypic resistance levels
in streptomycin-resistant Mycobacterium tuberculosis. Antimicrobial Agents &
Chemotherapy 40:2452-2454.
Cegielski, P., Blondal-Vink, K., Lambregts-van Weezenbeek, K., and Jaramillo,
E. 2006. Programmatic Control of Multidrug-Resistant Tuberculosis. In
Tuberculosis: A Comprehensive, International Approach. M.C. Raviglione,
editor. New York: Informa Healthcare USA, Inc. 845-868.
Pearson, M.L., Jereb, J.A., Frieden, T.R., Crawford, J.T., Davis, B.J., Dooley,
S.W., and Jarvis, W.R. 1992. Nosocomial transmission of multidrug-resistant
Mycobacterium tuberculosis. A risk to patients and health care workers.[see
comment]. Annals of Internal Medicine 117:191-196.
Frieden, T.R., Sterling, T., Pablos-Mendez, A., Kilburn, J.O., Cauthen, G.M., and
Dooley, S.W. 1993. The emergence of drug-resistant tuberculosis in New York
City.[see comment][erratum appears in N Engl J Med 1993 Jul 8;329(2):148].
New England Journal of Medicine 328:521-526.

71

29.

30.

31.

32.

33.

34.

35.

36.

37.

38.

39.

40.

41.

Centers for Disease, C. 1990. Nosocomial transmission of multidrug-resistant
tuberculosis to health-care workers and HIV-infected patients in an urban
hospital--Florida. MMWR - Morbidity & Mortality Weekly Report 39:718-722.
Centers for Disease, C. 1990. Outbreak of multidrug-resistant tuberculosis-Texas, California, and Pennsylvania. MMWR - Morbidity & Mortality Weekly
Report 39:369-372.
Moss, A.R., Alland, D., Telzak, E., Hewlett, D., Jr., Sharp, V., Chiliade, P.,
LaBombardi, V., Kabus, D., Hanna, B., Palumbo, L., et al. 1997. A city-wide
outbreak of a multiple-drug-resistant strain of Mycobacterium tuberculosis in
New York. International Journal of Tuberculosis & Lung Disease 1:115-121.
Frieden, T.R., Fujiwara, P.I., Washko, R.M., and Hamburg, M.A. 1995.
Tuberculosis in New York City--turning the tide. New England Journal of
Medicine 333:229-233.
Moro, M.L., Gori, A., Errante, I., Infuso, A., Franzetti, F., Sodano, L., and Iemoli,
E. 1998. An outbreak of multidrug-resistant tuberculosis involving HIV-infected
patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis
Outbreak Study Group. AIDS 12:1095-1102.
Centers for Disease Control and, P. 1996. Multidrug-resistant tuberculosis
outbreak on an HIV ward--Madrid, Spain, 1991-1995. MMWR - Morbidity &
Mortality Weekly Report 45:330-333.
Centers for Disease Control and, P. 1999. Primary multidrug-resistant
tuberculosis--Ivanovo Oblast, Russia, 1999. MMWR - Morbidity & Mortality
Weekly Report 48:661-664.
Ritacco, V., Di Lonardo, M., Reniero, A., Ambroggi, M., Barrera, L., Dambrosi,
A., Lopez, B., Isola, N., and de Kantor, I.N. 1997. Nosocomial spread of human
immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos
Aires.[see comment]. Journal of Infectious Diseases 176:637-642.
WHO. Anti-tuberculosis drug resistance in the world: third global report.
WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance
Surveillance. Geneva, 2004. (WHO/HTM/TB/2004.343).
Aziz, M.A., Wright, A., Laszlo, A., De Muynck, A., Portaels, F., Van Deun, A.,
Wells, C., Nunn, P., Blanc, L., Raviglione, M., et al. 2006. Epidemiology of
antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug
Resistance Surveillance): an updated analysis. Lancet 368:2142-2154.
Centers for Disease Control and, P. 2006. Emergence of Mycobacterium
tuberculosis with extensive resistance to second-line drugs--worldwide, 20002004. MMWR - Morbidity & Mortality Weekly Report 55:301-305.
Masjedi, M.R., Farnia, P., Sorooch, S., Pooramiri, M.V., Mansoori, S.D., Zarifi,
A.Z., Akbarvelayati, A., and Hoffner, S. 2006. Extensively drug-resistant
tuberculosis: 2 years of surveillance in Iran. Clinical Infectious Diseases 43:841847.
Gandhi, N.R., Moll, A., Sturm, A.W., Pawinski, R., Govender, T., Lalloo, U.,
Zeller, K., Andrews, J., and Friedland, G. 2006. Extensively drug-resistant
tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV
in a rural area of South Africa.[see comment]. Lancet 368:1575-1580.

72

42.

43.

44.

45.

46.

47.

48.

49.

50.

51.

52.
53.

DeRiemer, K., Garcia-Garcia, L., Bobadilla-del-Valle, M., Palacios-Martinez, M.,
Martinez-Gamboa, A., Small, P.M., Sifuentes-Osornio, J., and Ponce-de-Leon, A.
2005. Does DOTS work in populations with drug-resistant tuberculosis?[see
comment]. Lancet 365:1239-1245.
Farmer, P., Bayona, J., Becerra, M., Furin, J., Henry, C., Hiatt, H., Kim, J.Y.,
Mitnick, C., Nardell, E., and Shin, S. 1998. The dilemma of MDR-TB in the
global era.[see comment][comment]. International Journal of Tuberculosis &
Lung Disease 2:869-876.
Anuradha, B., Aparna, S., Hari Sai Priya, V., Vijaya Lakshmi, V., Akbar, Y.,
Suman Latha, G., and Murthy, K.J.R. 2006. Prevalence of drug resistance under
the DOTS strategy in Hyderabad, South India, 2001-2003.[erratum appears in Int
J Tuberc Lung Dis. 2006 Jun;10(6):708 Note: Priya, VHS [corrected to Hari Sai
Priya, V]; Lakshmi, VV [corrected to Vijaya Lakshmi, V]; Latha, GS [corrected
to Suman Latha, G]]. International Journal of Tuberculosis & Lung Disease
10:58-62.
Espinal, M.A., Kim, S.J., Suarez, P.G., Kam, K.M., Khomenko, A.G., Migliori,
G.B., Baez, J., Kochi, A., Dye, C., and Raviglione, M.C. 2000. Standard shortcourse chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6
countries.[see comment]. JAMA 283:2537-2545.
Rigouts, L., and Portaels, F. 1994. DNA fingerprints of Mycobacterium
tuberculosis do not change during the development of resistance to various
antituberculous drugs.[comment]. Tubercle & Lung Disease 75:160.
Portaels, F., Rigouts, L., Shamputa, I., Van Deun, A., and Abdel Aziz, M. 2006.
Tuberculosis Drug Resistance in the World. In Tuberculosis: A Comprehensive,
International Approach. M.C. Raviglione, editor. New York: Informa Healthcare
USA, Inc. 823-844.
Blower, S.M., and Chou, T. 2004. Modeling the emergence of the 'hot zones':
tuberculosis and the amplification dynamics of drug resistance. Nature Medicine
10:1111-1116.
Yong Kim, J., Shakow, A., Mate, K., Vanderwarker, C., Gupta, R., and Farmer, P.
2005. Limited good and limited vision: multidrug-resistant tuberculosis and
global health policy. Social Science & Medicine 61:847-859.
1999. Harvard Medical School / Open Society Institute. The Global Impact of
Drug Resistant Tuberculosis. Boston: Program in Infectious Disease and Social
Change, Harvard Medical School.
Gupta, R., Cegielski, J.P., Espinal, M.A., Henkens, M., Kim, J.Y., Lambregts-Van
Weezenbeek, C.S.B., Lee, J.-W., Raviglione, M.C., Suarez, P.G., and Varaine, F.
2002. Increasing transparency in partnerships for health--introducing the Green
Light Committee. Tropical Medicine & International Health 7:970-976.
Friedland, G.H. 2007. Tuberculosis, drug resistance, and HIV/AIDS: a triple
threat. Clin Infect Dis Rep In Press.
Weyer, K., and Kleeberg, H.H. 1992. Primary and acquired drug resistance in
adult black patients with tuberculosis in South Africa: results of a continuous
national drug resistance surveillance programme involvement. Tubercle & Lung
Disease 73:106-112.

73

54.

55.

56.

57.

58.

59.
60.
61.
62.
63.

64.

65.

66.
67.

Weyer, K., Groenewald, P., Zwarenstein, M., and Lombard, C.J. 1995.
Tuberculosis drug resistance in the Western Cape. South African Medical Journal
Suid-Afrikaanse Tydskrif Vir Geneeskunde 85:499-504.
Weyer, K., Lancaster, J., Balt, E., and Durrheim, D. 1998. Tuberculosis drug
resistance in Mpumalanga province, South Africa. In: Proceedings of the Global
Congress on Lung Health, 29th World Conference of the International Union
Against Tuberculosis and Lung Disease, Bangkok, Thailand, 23-26 November.
Int J Tuberc Lung Dis 2:S165.
Wilkinson, D., Pillay, M., Davies, G.R., and Sturm, A.W. 1996. Resistance to
antituberculosis drugs in rural South Africa: rates, patterns, risks, and
transmission dynamics. Transactions of the Royal Society of Tropical Medicine &
Hygiene 90:692-695.
Davies, G.R., Pillay, M., Sturm, A.W., and Wilkinson, D. 1999. Emergence of
multidrug-resistant tuberculosis in a community-based directly observed
treatment programme in rural South Africa. International Journal of Tuberculosis
& Lung Disease 3:799-804.
Weyer, K., Lancaster, J., Brand, J., van der Walk, M., and Levin, J. 2004. Survey
of Tuberculosis Drug Resistance in South Africa: 2001-2002. Pretoria: Medical
Research Council of South Africa.
Centers for Disease Control and, P. 2006. Trends in tuberculosis--United States,
2005. MMWR - Morbidity & Mortality Weekly Report 55:305-308.
2006. Case definition for extensively drug-resistant tuberculosis. Weekly
Epidemiological Record 81:408.
2006. Addressing the threat of tuberculosis caused by extensively drug-resistant
Mycobacterium tuberculosis. Weekly Epidemiological Record 81:386-390.
2006. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for
prevention and control. Weekly Epidemiological Record 81:430-432.
Boulahbal, F., and Heifets, L. 2006. Bacteriology of Tuberculosis. In
Tuberculosis: A Comprehensive, International Approach. M.C. Raviglione,
editor. New York: Informa Healthcare USA, Inc. 29-46.
Moore, D.A.J., Evans, C.A.W., Gilman, R.H., Caviedes, L., Coronel, J., Vivar,
A., Sanchez, E., Pinedo, Y., Saravia, J.C., Salazar, C., et al. 2006. Microscopicobservation drug-susceptibility assay for the diagnosis of TB.[see comment]. New
England Journal of Medicine 355:1539-1550.
Kim, S.J., Espinal, M.A., Abe, C., Bai, G.H., Boulahbal, F., Fattorin, L., Gilpin,
C., Hoffner, S., Kam, K.M., Martin-Casabona, N., et al. 2004. Is second-line antituberculosis drug susceptibility testing reliable? International Journal of
Tuberculosis & Lung Disease 8:1157-1158.
Kim, S.J. 2005. Drug-susceptibility testing in tuberculosis: methods and reliability
of results. European Respiratory Journal 25:564-569.
Casal, M., Vaquero, M., Rinder, H., Tortoli, E., Grosset, J., Rusch-Gerdes, S.,
Gutierrez, J., and Jarlier, V. 2005. A case-control study for multidrug-resistant
tuberculosis: risk factors in four European countries. Microbial Drug ResistanceMechanisms Epidemiology & Disease 11:62-67.

74

68.

El Sahly, H.M., Teeter, L.D., Pawlak, R.R., Musser, J.M., and Graviss, E.A. 2006.
Drug-resistant tuberculosis: a disease of target populations in Houston, Texas.
Journal of Infection 53:5-11.
69.
Conaty, S.J., Hayward, A.C., Story, A., Glynn, J.R., Drobniewski, F.A., and
Watson, J.M. 2004. Explaining risk factors for drug-resistant tuberculosis in
England and Wales: contribution of primary and secondary drug resistance.
Epidemiology & Infection 132:1099-1108.
70.
Pritchard, A.J., Hayward, A.C., Monk, P.N., and Neal, K.R. 2003. Risk factors for
drug resistant tuberculosis in Leicestershire--poor adherence to treatment remains
an important cause of resistance. Epidemiology & Infection 130:481-483.
71.
Sandman, L., Schluger, N.W., Davidow, A.L., and Bonk, S. 1999. Risk factors for
rifampin-monoresistant tuberculosis: A case-control study. American Journal of
Respiratory & Critical Care Medicine 159:468-472.
72.
Mannheimer, S.B., Sepkowitz, K.A., Stoeckle, M., Friedman, C.R., Hafner, A.,
and Riley, L.W. 1997. Risk factors and outcome of human immunodeficiency
virus-infected patients with sporadic multidrug-resistant tuberculosis in New York
City. International Journal of Tuberculosis & Lung Disease 1:319-325.
73.
Faustini, A., Hall, A.J., and Perucci, C.A. 2006. Risk factors for multidrug
resistant tuberculosis in Europe: a systematic review. Thorax 61:158-163.
74.
Telzak, E.E., Chirgwin, K.D., Nelson, E.T., Matts, J.P., Sepkowitz, K.A., Benson,
C.A., Perlman, D.C., and El-Sadr, W.M. 1999. Predictors for multidrug-resistant
tuberculosis among HIV-infected patients and response to specific drug regimens.
Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and
the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
International Journal of Tuberculosis & Lung Disease 3:337-343.
75.
Cohn, M., Oda, U., Kovitz, C., and Middlebrook, G. 1954. Studies on isoniazid
and tubercle bacilli. I. The isolation of
isoniazid-resistant mutants in vitro. American Review of Tuberculosis 70:465-475.
76.
Cohn, M., Kovitz, C., Oda, U., and Middlebrook, G. 1954. Studies on isoniazid
and tubercle bacilli. II. The growth requirements, catalase activities, and
pathogenic properties of isoniazid-resistant mutants. American Review of
Tuberculosis 70:641-664.
77.
Garcia-Garcia, M.L., Ponce de Leon, A., Jimenez-Corona, M.E., Jimenez-Corona,
A., Palacios-Martinez, M., Balandrano-Campos, S., Ferreyra-Reyes, L., JuarezSandino, L., Sifuentes-Osornio, J., Olivera-Diaz, H., et al. 2000. Clinical
consequences and transmissibility of drug-resistant tuberculosis in southern
Mexico.[see comment]. Archives of Internal Medicine 160:630-636.
78.
Burgos, M., DeRiemer, K., Small, P.M., Hopewell, P.C., and Daley, C.L. 2003.
Effect of drug resistance on the generation of secondary cases of tuberculosis.[see
comment]. Journal of Infectious Diseases 188:1878-1884.
79.
Frieden, T.R., Sherman, L.F., Maw, K.L., Fujiwara, P.I., Crawford, J.T., Nivin,
B., Sharp, V., Hewlett, D., Jr., Brudney, K., Alland, D., et al. 1996. A multiinstitutional outbreak of highly drug-resistant tuberculosis: epidemiology and
clinical outcomes.[see comment]. JAMA 276:1229-1235.
80.
Snider, D.E., Jr., Kelly, G.D., Cauthen, G.M., Thompson, N.J., and Kilburn, J.O.
1985. Infection and disease among contacts of tuberculosis cases with drug-

75

81.

82.

83.

84.

85.

86.

87.

88.

89.

90.

91.

resistant and drug-susceptible bacilli. American Review of Respiratory Disease
132:125-132.
Gordin, F.M., Nelson, E.T., Matts, J.P., Cohn, D.L., Ernst, J., Benator, D., Besch,
C.L., Crane, L.R., Sampson, J.H., Bragg, P.S., et al. 1996. The impact of human
immunodeficiency virus infection on drug-resistant tuberculosis. American
Journal of Respiratory & Critical Care Medicine 154:1478-1483.
Campos, P.E., Suarez, P.G., Sanchez, J., Zavala, D., Arevalo, J., Ticona, E.,
Nolan, C.M., Hooton, T.M., and Holmes, K.K. 2003. Multidrug-resistant
Mycobacterium tuberculosis in HIV-infected persons, Peru. Emerging Infectious
Diseases 9:1571-1578.
Punnotok, J., Shaffer, N., Naiwatanakul, T., Pumprueg, U., Subhannachart, P.,
Ittiravivongs, A., Chuchotthaworn, C., Ponglertnapagorn, P., Chantharojwong, N.,
Young, N.L., et al. 2000. Human immunodeficiency virus-related tuberculosis
and primary drug resistance in Bangkok, Thailand. International Journal of
Tuberculosis & Lung Disease 4:537-543.
Kenyon, T.A., Mwasekaga, M.J., Huebner, R., Rumisha, D., Binkin, N., and
Maganu, E. 1999. Low levels of drug resistance amidst rapidly increasing
tuberculosis and human immunodeficiency virus co-epidemics in Botswana.[see
comment]. International Journal of Tuberculosis & Lung Disease 3:4-11.
Churchyard, G.J., Corbett, E.L., Kleinschmidt, I., Mulder, D., and De Cock, K.M.
2000. Drug-resistant tuberculosis in South African gold miners: incidence and
associated factors. International Journal of Tuberculosis & Lung Disease 4:433440.
Espinal, M.A., Laserson, K., Camacho, M., Fusheng, Z., Kim, S.J., Tlali, R.E.,
Smith, I., Suarez, P., Antunes, M.L., George, A.G., et al. 2001. Determinants of
drug-resistant tuberculosis: analysis of 11 countries.[see comment]. International
Journal of Tuberculosis & Lung Disease 5:887-893.
Munsiff, S.S., Joseph, S., Ebrahimzadeh, A., and Frieden, T.R. 1997. Rifampinmonoresistant tuberculosis in New York City, 1993-1994. Clinical Infectious
Diseases 25:1465-1467.
Berning, S.E., Huitt, G.A., Iseman, M.D., and Peloquin, C.A. 1992.
Malabsorption of antituberculosis medications by a patient with AIDS. New
England Journal of Medicine 327:1817-1818.
Peloquin, C.A., MacPhee, A.A., and Berning, S.E. 1993. Malabsorption of
antimycobacterial medications. New England Journal of Medicine 329:11221123.
Patel, K.B., Belmonte, R., and Crowe, H.M. 1995. Drug malabsorption and
resistant tuberculosis in HIV-infected patients. New England Journal of Medicine
332:336-337.
Chaisson, R.E., Clermont, H.C., Holt, E.A., Cantave, M., Johnson, M.P.,
Atkinson, J., Davis, H., Boulos, R., Quinn, T.C., and Halsey, N.A. 1996. Sixmonth supervised intermittent tuberculosis therapy in Haitian patients with and
without HIV infection. American Journal of Respiratory & Critical Care
Medicine 154:1034-1038.

76

92.

93.

94.

95.

96.

97.

98.

99.

100.

101.

102.

Harries, A.D., Hargreaves, N.J., Kemp, J., Jindani, A., Enarson, D.A., Maher, D.,
and Salaniponi, F.M. 2001. Deaths from tuberculosis in sub-Saharan African
countries with a high prevalence of HIV-1.[see comment]. Lancet 357:1519-1523.
Murray, J., Sonnenberg, P., Shearer, S.C., and Godfrey-Faussett, P. 1999. Human
immunodeficiency virus and the outcome of treatment for new and recurrent
pulmonary tuberculosis in African patients. American Journal of Respiratory &
Critical Care Medicine 159:733-740.
Kawai, V., Soto, G., Gilman, R.H., Bautista, C.T., Caviedes, L., Huaroto, L.,
Ticona, E., Ortiz, J., Tovar, M., Chavez, V., et al. 2006. Tuberculosis mortality,
drug resistance, and infectiousness in patients with and without HIV infection in
Peru. Am J Trop Med Hyg 75:1027-1033.
Fischl, M.A., Daikos, G.L., Uttamchandani, R.B., Poblete, R.B., Moreno, J.N.,
Reyes, R.R., Boota, A.M., Thompson, L.M., Cleary, T.J., Oldham, S.A., et al.
1992. Clinical presentation and outcome of patients with HIV infection and
tuberculosis caused by multiple-drug-resistant bacilli. Annals of Internal Medicine
117:184-190.
Long, R., Scalcini, M., Manfreda, J., Jean-Baptiste, M., and Hershfield, E. 1991.
The impact of HIV on the usefulness of sputum smears for the diagnosis of
tuberculosis. American Journal of Public Health 81:1326-1328.
Johnson, J.L., Vjecha, M.J., Okwera, A., Hatanga, E., Byekwaso, F., Wolski, K.,
Aisu, T., Whalen, C.C., Huebner, R., Mugerwa, R.D., et al. 1998. Impact of
human immunodeficiency virus type-1 infection on the initial bacteriologic and
radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere
University-Case Western Reserve University Research Collaboration.
International Journal of Tuberculosis & Lung Disease 2:397-404.
Elliott, A.M., Namaambo, K., Allen, B.W., Luo, N., Hayes, R.J., Pobee, J.O., and
McAdam, K.P. 1993. Negative sputum smear results in HIV-positive patients
with pulmonary tuberculosis in Lusaka, Zambia. Tubercle & Lung Disease
74:191-194.
Greenberg, S.D., Frager, D., Suster, B., Walker, S., Stavropoulos, C., and
Rothpearl, A. 1994. Active pulmonary tuberculosis in patients with AIDS:
spectrum of radiographic findings (including a normal appearance). Radiology
193:115-119.
Palmieri, F., Girardi, E., Pellicelli, A.M., Rianda, A., Bordi, E., Rizzi, E.B.,
Petrosillo, N., and Ippolito, G. 2002. Pulmonary tuberculosis in HIV-infected
patients presenting with normal chest radiograph and negative sputum smear.
Infection 30:68-74.
Perlman, D.C., el-Sadr, W.M., Nelson, E.T., Matts, J.P., Telzak, E.E., Salomon,
N., Chirgwin, K., and Hafner, R. 1997. Variation of chest radiographic patterns in
pulmonary tuberculosis by degree of human immunodeficiency virus-related
immunosuppression. The Terry Beirn Community Programs for Clinical Research
on AIDS (CPCRA). The AIDS Clinical Trials Group (ACTG). Clinical Infectious
Diseases 25:242-246.
Post, F.A., Wood, R., and Pillay, G.P. 1995. Pulmonary tuberculosis in HIV
infection: radiographic appearance is related to CD4+ T-lymphocyte count.
Tubercle & Lung Disease 76:518-521.

77

103.

104.

105.

106.

107.

108.

109.

110.
111.
112.
113.

114.
115.

116.

Furin, J.J., Mitnick, C.D., Shin, S.S., Bayona, J., Becerra, M.C., Singler, J.M.,
Alcantara, F., Castanieda, C., Sanchez, E., Acha, J., et al. 2001. Occurrence of
serious adverse effects in patients receiving community-based therapy for
multidrug-resistant tuberculosis. International Journal of Tuberculosis & Lung
Disease 5:648-655.
Torun, T., Gungor, G., Ozmen, I., Bolukbai, Y., Maden, E., Bicakci, B., Atac, G.,
Sevim, T., and Tahaolu, K. 2005. Side effects associated with the treatment of
multidrug-resistant tuberculosis. International Journal of Tuberculosis & Lung
Disease 9:1373-1377.
Nathanson, E., Gupta, R., Huamani, P., Leimane, V., Pasechnikov, A.D., Tupasi,
T.E., Vink, K., Jaramillo, E., and Espinal, M.A. 2004. Adverse events in the
treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus
initiative. Int J Tuberc Lung Dis 8:1382-1384.
Mitnick, C., Bayona, J., Palacios, E., Shin, S., Furin, J., Alcantara, F., Sanchez,
E., Sarria, M., Becerra, M., Fawzi, M.C.S., et al. 2003. Community-based therapy
for multidrug-resistant tuberculosis in Lima, Peru. New England Journal of
Medicine 348:119-128.
Nathanson, E., Lambregts-van Weezenbeek, C., Rich, M.L., Gupta, R., Bayona,
J., Blondal, K., Caminero, J.A., Cegielski, J.P., Danilovits, M., Espinal, M.A., et
al. 2006. Multidrug-resistant tuberculosis management in resource-limited
settings. Emerging Infectious Diseases 12:1389-1397.
Drobniewski, F. 1997. Is death inevitable with multiresistant TB plus HIV
infection?[see comment][erratum appears in Lancet 1997 Mar 15;349(9054):810].
Lancet 349:71-72.
van der Wal, M., Weyer, K., and Lancastre, J. 2006. A standardised approach to
management of drug-resistant TB in South Africa. In South Africa Medical
Research Council Expert Consultation on Drug-Resistant Tuberculosis.
Johannesberg.
Leimane, V. 2006. MDR-TB and XDR-TB Management in Latvia. In Meeting of
the Global XDR-TB Task Force. Geneva.
Resch, S.C., Salomon, J.A., Murray, M., and Weinstein, M.C. 2006. Costeffectiveness of treating multidrug-resistant tuberculosis. PLoS Med 3:e241.
Republic of South Africa Department of Health. 2000. The South African
Tuberculosis Control Programme Practical Guidelines.
Migliori, G.B., Espinal, M., Danilova, I.D., Punga, V.V., Grzemska, M., and
Raviglione, M.C. 2002. Frequency of recurrence among MDR-tB cases
'successfully' treated with standardised short-course chemotherapy. International
Journal of Tuberculosis & Lung Disease 6:858-864.
Rouillon, A., Perdrizet, S., and Parrot, R. 1976. Transmission of tubercle bacilli:
The effects of chemotherapy. Tubercle 57:275-299.
Colebunders, R., and Bastian, I. 2000. A review of the diagnosis and treatment of
smear-negative pulmonary tuberculosis. International Journal of Tuberculosis &
Lung Disease 4:97-107.
Manosuthi, W., Chottanapand, S., Thongyen, S., Chaovavanich, A., and
Sungkanuparph, S. 2006. Survival rate and risk factors of mortality among

78

117.

118.

119.

HIV/tuberculosis-coinfected patients with and without antiretroviral therapy.
Journal of Acquired Immune Deficiency Syndromes: JAIDS 43:42-46.
Lawn, S.D., Myer, L., Bekker, L.-G., and Wood, R. 2006. Burden of tuberculosis
in an antiretroviral treatment programme in sub-Saharan Africa: impact on
treatment outcomes and implications for tuberculosis control. AIDS 20:16051612.
Harries, A.D., Nyangulu, D.S., Kang'ombe, C., Ndalama, D., Glynn, J.R., Banda,
H., Wirima, J.J., Salaniponi, F.M., Liomba, G., Maher, D., et al. 1998. Treatment
outcome of an unselected cohort of tuberculosis patients in relation to human
immunodeficiency virus serostatus in Zomba Hospital, Malawi. Transactions of
the Royal Society of Tropical Medicine & Hygiene 92:343-347.
Sturm, A.W. 2006. The UKZN "Outbreak". In Expert Consultation on XDR-TB.
Johannesburg.

79

